<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS156182</article-id><article-id pub-id-type="doi">10.1101/2022.10.21.513088</article-id><article-id pub-id-type="archive">PPR562145</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Brain DNA methylomic analysis of frontotemporal lobar degeneration reveals <italic>OTUD4</italic> in shared dysregulated signatures across pathological subtypes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fodder</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Murthy</surname><given-names>Megha</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rizzu</surname><given-names>Patrizia</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Toomey</surname><given-names>Christina E.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hasan</surname><given-names>Rahat</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Humphrey</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Raj</surname><given-names>Towfique</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lunnon</surname><given-names>Katie</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mill</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Heutink</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lashley</surname><given-names>Tammaryn</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bettencourt</surname><given-names>Conceição</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK</aff><aff id="A2"><label>2</label>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK</aff><aff id="A3"><label>3</label>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK</aff><aff id="A4"><label>4</label>German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany</aff><aff id="A5"><label>5</label>The Francis Crick Institute, London, UK</aff><aff id="A6"><label>6</label>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A7"><label>7</label>Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK</aff><aff id="A8"><label>8</label>Alector, Inc., South San Francisco, CA, USA</aff><author-notes><corresp id="CR1">
<label>*</label>Corresponding Author: Conceição Bettencourt, PhD Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology Queen Square Brain Bank for Neurological Disorders 1 Wakefield Street London WC1N 1PJ United Kingdom <email>c.bettencourt@ucl.ac.uk</email>
</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>27</day><month>10</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>22</day><month>10</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Frontotemporal lobar degeneration (FTLD) is an umbrella term describing the neuropathology of a clinically, genetically and pathologically heterogeneous group of diseases, including frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). Among the major FTLD pathological subgroups, FTLD with TDP-43 positive inclusions (FTLD-TDP) and FTLD with tau positive inclusions (FTLD-tau) are the most common, representing about 90% of the cases. Although alterations in DNA methylation have been consistently associated with neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, little is known for FTLD and its heterogeneous subgroups and subtypes. The main goal of this study was to investigate DNA methylation variation in FTLD-TDP and FTLD-tau. We used frontal cortex genome-wide DNA methylation profiles from three FTLD cohorts (234 individuals), generated using the Illumina 450K or EPIC microarray. We performed epigenome-wide association studies (EWAS) for each cohort followed by meta-analysis to identify shared differential methylated loci across FTLD subgroups/subtypes. Additionally, we used weighted gene correlation network analysis to identify co-methylation signatures associated with FTLD and other disease-related traits. Wherever possible, we also incorporated relevant gene/protein expression data. After accounting for a conservative Bonferroni multiple testing correction, the EWAS meta-analysis revealed two differentially methylated loci in FTLD, one annotated to <italic>OTUD4</italic> (5’UTR-shore) and the other to <italic>NFATC1</italic> (gene body-island). Of these loci, <italic>OTUD4</italic> showed consistent upregulation of mRNA and protein expression in FTLD. Additionally, in the three independent co-methylation networks, OTUD4-containing modules were enriched for EWAS meta-analysis top loci and were strongly associated with the FTLD status. These co-methylation modules were enriched for genes implicated in the ubiquitin system, RNA/stress granule formation and glutamatergic synaptic signalling. Altogether, our findings identified novel FTLD-associated loci, and support a role for DNA methylation as a mechanism involved in the dysregulation of biological processes relevant to FTLD, highlighting novel potential avenues for therapeutic development.</p></abstract><kwd-group><kwd>DNA methylation</kwd><kwd>frontotemporal dementia</kwd><kwd>progressive supranuclear palsy</kwd><kwd>human brain tissue</kwd><kwd>EWAS</kwd><kwd>co-methylation</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Frontotemporal lobar degeneration (FTLD) is an umbrella term describing the neuropathology of a group of neurodegenerative disorders, which are characterised by the selective degeneration of the frontal and temporal lobes of the brain. These disorders are clinically, pathologically and genetically heterogeneous. Clinically, patients with FTLD frequently present with frontotemporal dementia (FTD), which is the second most common form of early onset dementia and is often associated with behavioural and language changes. A fraction of patients may present with or develop Parkinsonism as part of their disease, including those with progressive supranuclear palsy (PSP), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). An overlap with amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) is also observed in a proportion of patients with FTLD, highlighting a spectrum of clinical phenotypes that relate to shared neuropathologic features [<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R41">41</xref>].</p><p id="P3">A considerable number of FTLD cases report a positive family history (30-50%), and the majority of familial cases can be attributed to mutations in three genes, namely chromosome 9 open reading frame 72 (<italic>C9orf72</italic>), progranulin (<italic>GRN</italic>), and microtubule-associated protein tau (<italic>MAPT</italic>). Apart from those cases in which a genetic mutation has been identified, neuropathological assessment is essential to confirm the disease entity underlying FTLD. The neuropathological classification of FTLDs, based on the presence/absence of specific proteinaceous inclusions, recognizes five major subgroups. FTLD with 431kDa transactive response DNA-binding protein (TDP-43) positive inclusions (FTLD-TDP), and with tau positive inclusions (FTLD-tau), account for the vast majority of cases, representing around 50% and 40% of FTLD cases, respectively [<xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R58">58</xref>].</p><p id="P4">Even though progress has been made in identifying genetic risk factors for diseases under the FTLD umbrella [<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R66">66</xref>, <xref ref-type="bibr" rid="R87">87</xref>], the molecular mechanisms driving FTLD pathology are not completely understood. Mounting evidence reveals changes in the FTLD brain transcriptional landscapes [<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R81">81</xref>]. However, studies investigating non-sequence-based regulatory mechanisms such as epigenetic modifications in FTLD brain tissue are limited [<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R83">83</xref>, <xref ref-type="bibr" rid="R86">86</xref>]. Variable DNA methylation, the most well studied epigenetic modification, has consistently been associated with Alzheimer’s disease pathology in epigenome-wide studies (EWAS) and subsequent meta-analyses [<xref ref-type="bibr" rid="R72">72</xref>, <xref ref-type="bibr" rid="R74">74</xref>, <xref ref-type="bibr" rid="R89">89</xref>]. In FTLD, brain tissue EWAS are scarce and limited to a single PSP study [<xref ref-type="bibr" rid="R83">83</xref>].</p><p id="P5">To investigate further the relevance of DNA methylation variation in FTLD, we set out a study investigating epigenome-wide DNA methylation variation in frontal lobe tissue from three cohorts, spanning different subtypes of FTLD-TDP and FTLD-tau subgroups, followed by an EWAS meta-analysis, co-methylation network analysis in each cohort, and subsequent module preservation analysis in the other datasets. Through the EWAS meta-analysis we identified two differentially methylated loci shared across the FTLD subgroups and subtypes after a conservative Bonferroni correction for multiple testing. These methylation sites were annotated to <italic>OTUD4</italic> (5’UTR-shore) and <italic>NFATC1</italic> (gene body-island). We also identified co-methylation modules associated with the FTLD status, FTLD subtypes, and pathological features (e.g., brain atrophy and severity of neuronal loss). Functional and cellular enrichment analyses have shown an overrepresentation of gene ontology terms related to regulation of gene expression and the ubiquitin system as well as specific cell types, including pyramidal neurons and endothelial cells, across FTLD subgroups and subtypes. In all three independent co-methylation networks, OTUD4-containing modules were enriched for top EWAS meta-analysis loci, and were strongly associated with the disease status, further supporting their role in FTLD. Our findings implicate DNA methylation in the dysregulation of important processes in FTLD, including the ubiquitin system, RNA/stress granule formation and glutamatergic synaptic signalling.</p></sec><sec id="S2" sec-type="methods"><title>Methods</title><sec id="S3"><title>Demographic and clinical characteristics of post-mortem brain donors</title><p id="P6">For FTLD cohort 1 (FTLD1, N=23), all post-mortem tissues originated from brains donated to the Queen Square Brain Bank archives, where tissues are stored under a licence from the Human Tissue authority (No. 12198). Both the brain donation programme and protocols have received ethical approval for donation and research by the NRES Committee London – Central. All cases were characterized by age, gender, disease history (including disease onset and duration) as well as neuropathological findings. For FTLD cohort 2 (FTLD2, N=48), all post-mortem tissues were obtained under a Material Transfer Agreement from the</p><p id="P7">Netherlands Brain Bank, and MRC Kings College London, as described by Menden et al. [<xref ref-type="bibr" rid="R53">53</xref>]. For FTLD cohort 3 (FTLD3, N=163, after quality control), data made available by Weber et al. [<xref ref-type="bibr" rid="R83">83</xref>] was retrieved from GEO (accession code GSE75704). <xref ref-type="fig" rid="F1">Figure 1</xref> shows an outline of the study design and analysis framework. More details on each cohort are presented in <xref ref-type="table" rid="T1">Table 1</xref>.</p></sec><sec id="S4"><title>Measures of brain atrophy, neuronal cell loss and pathology related traits</title><p id="P8">For FTLD1 and a proportion of cohort FTLD2, formalin-fixed paraffin-embedded (FFPE) sections were also available for more detailed neuropathological evaluations, including sections stained for standard haematoxylin and eosin (H&amp;E). These FFPE sections were from the opposite brain hemisphere with respect to the frozen tissue used for the DNA methylation profiling.</p><p id="P9">For FTLD1 and FTLD2, microscopic atrophy was assessed on H&amp;E stained slides, by examining the cortical thickness and neuronal loss in the frontal and temporal cortices. A four point grading system was used in comparison to a neurological normal control with no underlying neurodegenerative changes: 0 - the cortical thickness was within normal limits and no neuronal loss was observed; 1 - reduction in cortical thickness but the number of neurons was comparable to normal levels; 2 - reduction in cortical thickness and reduction in the numbers of neurons; 3 - severe reduction in cortical thickness and no neurons observed. For each region, the microscopic atrophy was scored semi-quantitatively by an experienced observer blinded to clinical, histopathological and genetic status, at an objective magnification of×20. Macroscopic atrophy was also determined for FTLD1 based on observations of gyri and sulci from the coronal slices observed during brain cutting procedures. Levels of atrophy were graded, as previously described [<xref ref-type="bibr" rid="R69">69</xref>], into four stages: none, mild, moderate, and severe. These neuropathological scores of the frontal and temporal regions were used in the module-trait correlations with the DNA co-methylation network modules.</p></sec><sec id="S5"><title>DNA methylation profiling and data quality control</title><p id="P10">For FTLD1, genomic DNA was extracted from carefully dissected flash frozen frontal cortex grey matter tissue using standard protocols. Bisulfite conversion was performed with the EZ DNA Methylation Kit (Zymo Research) using 500 ng of genomic DNA. For FTLD2 and FTLD3, DNA extractions and bisulfite conversions were performed previously as described by Menden et al. [<xref ref-type="bibr" rid="R53">53</xref>] and Weber et al. [<xref ref-type="bibr" rid="R83">83</xref>]. Genome-wide methylation profiles were generated using the Infinium HumanMethylationEPIC BeadChip (Illumina) for FTLD1 and FTLD2, or the Infinium HumanMethylation450 BeadChip (Illumina) for FTLD3, as per the manufacturer’s instructions.</p><p id="P11">Beta values ranging from 0 to 1 (approximately 0% to 100% methylation, respectively), were used to estimate the methylation levels of each CpG site using the ratio of intensities between methylated and unmethylated alleles. Data analysis was conducted using several R Bioconductor packages as previously described [<xref ref-type="bibr" rid="R11">11</xref>]. All three cohorts were subjected to harmonized quality control checks and pre-processing. Briefly, raw data (idat files) were imported and subjected to rigorous pre-processing and thorough quality control checks using minfi [<xref ref-type="bibr" rid="R4">4</xref>], wateRmelon [<xref ref-type="bibr" rid="R67">67</xref>], and ChAMP packages [<xref ref-type="bibr" rid="R76">76</xref>]. The following criteria were used to exclude probes that did not pass quality control checks from further analysis: 1) poor quality, 2) cross reactive, 3) included common genetic variants, and 4) mapped to X or Y chromosome. In addition, samples were dropped during quality control if: 1) they presented with a high failure rate (≥ 2% of probes), 2) the predicted sex did not match the phenotypic sex, and 3) they clustered inappropriately on multidimensional scaling analysis. Beta values were normalised with ChAMP using the Beta-Mixture Quantile (BMIQ) normalisation method. M-values, computed as the logit transformation of beta values, were used for all statistical analysis, as recommended by Du et al. [<xref ref-type="bibr" rid="R22">22</xref>], owing to their reduced heteroscedasticity (as opposed to beta-values) and improved statistical validity for differential methylation analysis.</p><p id="P12">As significant batch effects were detected during quality control checks, and different FTLD subgroups/subtypes were studied in FTLD1-3, the three cohorts were analysed separately first and then meta-analysed. Similarly, co-methylation network analyses were conducted on each cohort separately, and module preservations were then cross-checked with data from the other cohorts (as described in more detail below).</p></sec><sec id="S6"><title>Cell type deconvolution based on DNA methylation data</title><p id="P13">As DNA methylation patterns are often cell-type specific, changes in different brain cell-type proportions constitute an important confounding factor for DNA methylation studies performed on ‘bulk’ brain tissue. We used a novel cell-type deconvolution reference panel recently described by Shireby et al. [<xref ref-type="bibr" rid="R72">72</xref>] which brings more granularity and expands previous methods that account only for neuronal (NeuN+) versus all other cell types (NeuN-). This new method uses novel DNA methylation data obtained from fluorescence activated sorted nuclei from cortical brain tissue to estimate the relative proportions of neurons (NeuN+), oligodendrocytes (SOX10+) and other glial brain cell types (Double- [NeuN-/SOX10-]). Celltype proportions in bulk brain tissue were thus estimated using the CETYGO (CELL TYpe deconvolution GOodness) package (<ext-link ext-link-type="uri" xlink:href="https://github.com/ds420/CETYGO">https://github.com/ds420/CETYGO</ext-link>), and the sorted celltype reference datasets as described by Shireby et al. [<xref ref-type="bibr" rid="R72">72</xref>]. Pairwise comparisons between FTLD cases and controls were conducted using Wilcoxon rank sum test with Benjamini-Hochberg correction for multiple testing, and adjusted p&lt;0.05 was considered significant.</p></sec><sec id="S7"><title>Differential methylation analysis and EWAS meta-analysis</title><p id="P14">We applied linear regression models (<xref ref-type="table" rid="T1">Table 1</xref>) using the M-values as the input to identify associations between DNA methylation variation at specific CpG sites and FTLD using the limma package [<xref ref-type="bibr" rid="R64">64</xref>]. For FTLD1, we have accounted for possible confounding factors, such as age and sex as well as factors detected in principal components 1 and 2 as seen in Singular Value Decomposition (SVD) plots (ChAMP package), which included cell proportions (SOX10+ and Double-) and sample position in the array. Using this regression model, no surrogate variables were detected with the num.sv function of the SVA package [<xref ref-type="bibr" rid="R42">42</xref>], meaning there were no remaining unknown, unmodelled, or latent sources of noise [<xref ref-type="bibr" rid="R64">64</xref>]. The same process was applied to FTLD2 and FTLD3. The model for FTLD2 was further adjusted for slide, whereas for FTLD3, the model was further adjusted for slide and one surrogate variable (<xref ref-type="table" rid="T1">Table 1</xref>). False discovery rate (FDR) adjusted p-values &lt;0.05 were considered genome-wide significant.</p><p id="P15">We used the estimated coefficients and SEs obtained from the regression models, described above for the three FTLD cohorts, to undertake an inverse variance meta-analysis using the metagen function from the meta R package [<xref ref-type="bibr" rid="R8">8</xref>]. Only methylation probes present in all datasets (N= 363,781) were considered for this analysis. When reporting differentially methylated sites, a conservative Bonferroni significance was defined as p&lt;1.374×10<sup>−7</sup> (p &lt; 0.05/363,781) to account for multiple testing. We report random-effects meta-analysis results as the three cohorts included different FTLD subgroups/subtypes according to the neuropathological classification possibly leading to high heterogeneity in the meta-analysis. We also used a less stringent FDR adjusted p &lt; 0.10 to report top meta-analysis loci, all of which were then investigated in the co-methylation networks.</p></sec><sec id="S8"><title>Co-methylation network analysis</title><p id="P16">To identify clusters of highly correlated CpGs (co-methylation modules) in an unsupervised manner, i.e., agnostic of gene ontology, we used a systems biology approach based on weighted gene correlation network analysis (WGCNA) [<xref ref-type="bibr" rid="R38">38</xref>]. For this analysis, we focused on CpGs present in all three FTLD datasets, non-intergenic CpGs (i.e. CpGs annotated to genes), and selected the top 20% with the highest variance across individuals in each cohort regardless of their disease status (i.e., most variable 56,001 CpG sites per cohort). After outlier exclusion, a total of 23, 42 and 157 samples remained in the FTLD1, FTLD2 and FTLD3 cohorts, respectively. For each network, we used as input the M-values adjusted for the covariates included in the models described above (<xref ref-type="table" rid="T1">Table 1</xref>) and constructed signed networks. Modules were calculated using the WGCNA blockwiseModules function, with a minimum module size of 200 and a soft-thresholding power of 16, 10 and 12 for the FTLD1, FTLD2 and FTLD3 networks, respectively. Module membership (MM) was then reassigned for each network using the applyKMeans function of the CoExpNets package [<xref ref-type="bibr" rid="R13">13</xref>]. Highly connected CpGs within a module (hub CpGs) present with high MM values to the respective module. In the results section, we refer to hub CpGs as those with the highest MM within a given module.</p><p id="P17">By using a principal component analysis on the CpG methylation values within each module, the CpGs inside each module were represented by a weighted average, the module eigengene (ME). The MEs were then correlated with the FTLD status, FTLD subtypes, and other sample traits, including disease onset and duration, measures of macroscopic atrophy and neuronal loss scores, and other pathology related traits, as available for each cohort.</p><p id="P18">To gain insights into the biology underlying the FTLD-related modules, we carried out functional enrichment for CpGs mapping to genes using the default parameters of clusterProfiler [<xref ref-type="bibr" rid="R85">85</xref>]. We also carried out cell-type enrichment analysis on the FTLD-related modules using the package EWCE [<xref ref-type="bibr" rid="R73">73</xref>] and associated single-cell transcriptomic data [<xref ref-type="bibr" rid="R88">88</xref>].</p></sec><sec id="S9"><title>DNA methylation cross-network module preservation analysis</title><p id="P19">As a method for differential network analysis, i.e., to identify which co-methylation modules in each of the three generated FTLD networks were preserved (i.e., shared) or perturbed (i.e., unique) in the other two datasets, we employed module preservation analysis, as described by Langfelder et al. [<xref ref-type="bibr" rid="R39">39</xref>]. For each network (taken as the “reference dataset”), module preservation in the other two datasets (the “test data”) was calculated using the modulePreservation function implemented in WGCNA. In all instances, the “test data” contained methylation values (adjusted M-values) for the 56,001 CpG sites used to construct the “reference dataset” network. A total of 200 permutations for each preservation analysis was used. As a measurement of module preservation, we used the Z-summary statistic (a composite measure to summarise multiple preservation statistics). A Z-summary greater than 10 indicates a strong preservation of this module in the “test data”, a Z-summary of between 2 and 10 indicates moderate preservation, and a Z-summary less than 2 indicates no preservation.</p></sec><sec id="S10"><title>Comparisons of DNA methylation hits with FTLD frontal/temporal cortex gene expression data</title><p id="P20">To examine the gene expression patterns of the EWAS meta-analysis gene hits, we used previously published transcriptomics data from bulk frontal cortex tissue of FTLD-TDP cases and controls [<xref ref-type="bibr" rid="R30">30</xref>] as well as bulk temporal cortex tissue of FTLD-tau cases (PSP) and controls [<xref ref-type="bibr" rid="R82">82</xref>]. To further infer the expression patterns of selected DNA methylation hit genes in specific brain cell types, we also correlated gene expression levels (adjusted for age, sex, and RNA integrity number) with cellular proportions using data from Hasan et al. [<xref ref-type="bibr" rid="R30">30</xref>], with cellular proportions estimated using the method described by Mathys et al. [<xref ref-type="bibr" rid="R50">50</xref>]</p></sec><sec id="S11"><title>Comparisons of DNA methylation hits with FTLD-TDP frontal cortex proteomics data</title><p id="P21">To examine the gene expression patterns of the EWAS meta-analysis gene hits at the protein level, we used proteomics data from FTLD-TDP and controls. Briefly, frontal cortex homogenate of frozen post-mortem human brain tissue was prepared from control (N=6), FTLD-TDP type A with <italic>C9orf72</italic> repeat expansion (N=6), and FTLD-TDP type C (N=6) cases. Proteins in both the soluble supernatant and the insoluble pellet fraction were analysed, and samples were pooled per disease group (three cases per pooled sample). Proteins were quantitated using 2D-LCMS and UDMSe label-free proteomics and SYNAPT G2- Si High Definition mass spectrometer operating in ion mobility mode. Data was processed using Progenesis software, as previously described [<xref ref-type="bibr" rid="R78">78</xref>]. A total of 6114 proteins were detected in the supernatant, and 5108 in the pellet, with an overlap in some proteins that were found both in the supernatant and pellet. Fold-changes between FTLD-TDP subtypes compared to controls were calculated. Of the Bonferroni significant EWAS meta-analysis hits, only the OTUD4 protein was detected (both in the supernatant and in the pellet).</p></sec><sec id="S12"><title>Comparisons of DNA methylation hits with additional datasets</title><p id="P22">We further investigated the normal expression patterns of the meta-analysis gene hits both in the human and mouse brains using single nuclei RNAseq data from the Allen Brain Map (<ext-link ext-link-type="uri" xlink:href="https://celltypes.brain-map.org/">https://celltypes.brain-map.org/</ext-link>)[<xref ref-type="bibr" rid="R7">7</xref>], and data from the Allen Mouse Brain Atlas (<ext-link ext-link-type="uri" xlink:href="http://mouse.brain-map.org">http://mouse.brain-map.org</ext-link>)[<xref ref-type="bibr" rid="R43">43</xref>]. Given the OTUD4-related findings, we investigated the list of cortical tissue OTUD4 protein interactors made available by Das et al. [<xref ref-type="bibr" rid="R20">20</xref>]. The RNA granule database (<ext-link ext-link-type="uri" xlink:href="http://rnagranuledb.lunenfeld.ca/">http://rnagranuledb.lunenfeld.ca/</ext-link>)collates curated literature evidence that support gene or protein association with the stress granules (SGs) and P-bodies (PBs). We used a list of tier 1 genes from the RNA granule database version 2.0 for comparisons with the lists of genes composing the three <italic>OTUD4</italic> FTLD-associated co-methylation modules.</p></sec><sec id="S13"><title>OTUD4 immunohistochemical staining</title><p id="P23">To investigate tissue expression patterns of OTUD4 protein across the human cortex, FFPE frontal cortex tissue from 7 FTLD cases (4 FTLD-TDP type A and 3 FTLD-TDP type C) and 3 controls (overlapping with FTLD1) were utilized. Briefly, eight-micrometre-thick sections cut from the FFPE blocks were immunostained using a standard avidin-biotin-peroxidase complex method with di-aminobenzidine as the chromogen [<xref ref-type="bibr" rid="R40">40</xref>]. The rabbit anti-OTUD4 antibody (Atlas Antibodies HPA036623, 1:200) was used, along with heat antigen retrieval pre-treatment prior to application of the primary antibody. The samples were mounted and examined using a light microscope.</p></sec></sec><sec id="S14" sec-type="results"><title>Results</title><sec id="S15"><title>Cell-type deconvolution based on DNA methylation data highlights important cellular composition differences in FTLD</title><p id="P24">To estimate brain cell-type proportions in our bulk frontal cortex DNA methylation datasets, we used a refined cell-type deconvolution algorithm based on reference DNA methylation profiles from purified nuclei from neurons (NeuN+), oligodendrocytes (SOX10+) and other brain cell types (NeuN-/SOX10-)[<xref ref-type="bibr" rid="R72">72</xref>]. This new model controls better for cellular heterogeneity in bulk cortex tissue compared to previous models, which account only for neuronal (NeuN+) versus all glial cells (NeuN-). Within each sample group, we observed extensive variability in cell-type proportions across cell types (<xref ref-type="fig" rid="F2">Fig. 2</xref>). When comparing disease cases with controls, no overall differences were overall detected in the proportions of oligodendrocytes (SOX10+) and other glial cells (NeuN-/SOX10-) after accounting for multiple testing corrections. However, with the exception of the PSP cases (FTLD3), all FTLD subgroups/subtypes showed a significant decrease in neuronal proportions compared to controls (Wilcoxon rank sum test, adjusted-p&lt;0.05), as expected in neurodegenerative diseases. These findings highlight the importance of adjusting for cell-type proportions in bulk tissue EWAS studies. Accounting for this allowed us to identify DNA methylation changes that are relevant to the disease rather than merely reflecting changes in cell-type composition, which could be related partly to the disease pathogenesis itself and partly due to technical issues (e.g., a result of capturing different proportions of grey and white matter during tissue dissection).</p></sec><sec id="S16"><title>Frontal cortex case-control EWAS meta-analysis identifies shared differentially methylated CpG sites across FTLD pathological subgroups and subtypes</title><p id="P25">First, we investigated DNA methylation variation in specific loci across the genome as covered by the 450K/EPIC arrays, using linear regressions models to perform cohort-specific case-control EWAS. For FTLD1 and FTLD2, which comprise heterogeneous cases with sporadic and genetic forms of FTLD-TDP and FTLD-tau pathology, no genome-wide significant CpGs were identified. For FTLD3, which only includes cases with FTLD-tau pathology (sporadic PSP), 234 differentially methylated positions were identified (Supplementary Table S1, Online Resource). The top differentially methylated CpG in the FTLD3 cohort was cg09202319, which was hypomethylated in FTLD-tau (PSP) compared to controls (adjusted-p=6.54 × 10<sup>-8</sup>). This CpG mapped to a CpG island in the promoter region of <italic>PFDN6</italic> (Prefoldin Subunit 6), which is involved in promoting the assembly of cytoskeletal proteins [<xref ref-type="bibr" rid="R44">44</xref>]. Supplementary <xref ref-type="fig" rid="F1">figure 1</xref> (Online Resource) shows the quantile-quantile (Q-Q) plots for each of the single cohort-specific EWAS.</p><p id="P26">Second, we meta-analysed the single cohort EWAS results, enabling an analysis of FTLD-associated differential cortical DNA methylation using tissue from 234 individuals. After a conservative Bonferroni adjustment for multiple testing (p&lt;1.37 × 10<sup>−7</sup>), the meta-analysis identified two differentially methylated CpGs in FTLD compared to controls, regardless of the pathological subgroup (FTLD-TDP or FTLD-tau), and corresponding subtypes (<xref ref-type="fig" rid="F3">Fig. 3</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2</xref>, Supplementary Table S2, Online Resource). The top CpG was annotated to a shore in the 5’UTR of <italic>OTUD4</italic> and was hypomethylated in FTLD compared to controls, whereas the other was annotated to a CpG island in the body of <italic>NFATC1</italic> and hypermethylated in FTLD compared to controls (<xref ref-type="fig" rid="F3">Fig. 3</xref>). The direction of the effect was consistent across the three FTLD cohorts for these two hits, as well as for nine additional top meta-analysis loci obtained when considering a less stringent FDR p &lt; 0.10 multiple testing correction (<xref ref-type="fig" rid="F3">Fig. 3</xref>; Supplementary Table S2, Online Resource). Of note, none of these meta-analysis top differentially methylated sites showed epigenome-wide significant changes in FTLD3 alone (Supplementary Table S1, Online Resource) or in previous Alzheimer’s disease EWAS meta-analyses (Supplementary Table S2, Online Resource).</p></sec><sec id="S17"><title>Frontal cortex FTLD EWAS meta-analysis hits are consistent with downstream changes in mRNA and protein expression patterns</title><p id="P27">To investigate the downstream consequences of DNA methylation variation on gene expression in FTLD, we investigated available FTLD-TDP and FTLD-tau transcriptomic data [<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R82">82</xref>], as well as FTLD-TDP proteomics data. From the EWAS meta-analysis hits passing Bonferroni correction, consistent results were observed in both FTLD-TDP (frontal cortex) and FTLD-tau (temporal cortex) for <italic>OTUD4,</italic> which showed higher mRNA expression levels in FTLD cases compared to controls (<xref ref-type="fig" rid="F4">Fig. 4</xref>). For <italic>NFATC1,</italic> increased expression was observed in FTLD-TDP when compared to controls (<xref ref-type="fig" rid="F4">Fig. 4</xref>). However, this increase in expression was not observed in the FTLD-Tau, as seen in data from Wang et al. [<xref ref-type="bibr" rid="R82">82</xref>]. Of the nine additional top meta-analysis loci, <italic>ZNF804A</italic> showed lower mRNA expression levels and <italic>IMPA2</italic> showed higher mRNA expression levels in FTLD cases compared to controls (p &lt; 0.05, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>, Online Resource). DNA methylation levels in upstream regulatory regions are often inversely associated with gene expression levels [<xref ref-type="bibr" rid="R59">59</xref>, <xref ref-type="bibr" rid="R79">79</xref>]. Therefore, lower methylation levels in CpGs annotated to 5’UTR in <italic>OTUD4</italic> and to TSS200 in <italic>IMPA2,</italic> and higher expression of these genes in FTLD compared to controls, meets such expectations. On the other hand, DNA methylation levels in gene bodies are usually positively associated with gene expression. Again, results align with this in the case of <italic>NFATC1</italic> (which showed higher methylation and higher expression in FTLD-TDP compared to controls) and <italic>ZNF804A</italic> (which showed lower methylation and lower expression in FTLD).</p><p id="P28">Only one of the two Bonferroni adjusted meta-analysis gene hits were detected in the frontal cortex proteomics data. OTUD4 protein was upregulated in FTLD-TDP in types A and C compared to controls (<xref ref-type="fig" rid="F5">Fig. 5</xref>), with the highest fold-change being observed in type C for the supernatant soluble fraction (fold-change = 14.72). These findings are in line with our observations with the RNAseq data and support consistent dysregulation of the <italic>OTUD4</italic> EWAS meta-analysis hit in FTLD. Therefore, we further investigated the patterns of OTUD4 protein expression in the frontal cortex and performed anti-OTUD4 immunohistochemical analysis (<xref ref-type="fig" rid="F6">Fig. 6</xref>) using FTLD-TDP types A and C cases as well as controls that overlap with those used in the DNA methylation analysis (subset of the FTLD1 cohort). Minimal neuronal cytoplasmic staining was observed in the normal controls. However, in the FTLD-TDP cases, an increase in cytoplasmic staining intensity was observed in both the grey and white matter. In the grey matter, neuronal cytoplasmic staining was seen together with glial nuclear staining. In the white matter, there was an increase in glial staining. These results concur with the results from our proteomics and transcriptomics data.</p></sec><sec id="S18"><title>DNA co-methylation modules are associated with the FTLD status, FTLD pathological subtypes, and disease-related traits</title><p id="P29">To provide insight into higher order relationships across DNA methylation sites (CpGs), we used an agnostic systems biology approach based on WGCNA and constructed co-methylation networks. Considering the top 20% most variable CpGs in each of the 3 cohorts (N = 56,001 CpGs), we identified clusters of highly correlated CpGs, henceforth called co-methylation modules, each assigned a colour name.</p><p id="P30">For the FTLD1, FTLD2 and FTLD3 networks, 9/33 (p&lt;0.002, 0.05/33 modules), 16/49 (p&lt;0.001, 0.05/49 modules) and 10/14 (p&lt;0.004, 0.05/14 modules) co-methylation modules were found to be associated with the disease status (i.e., FTLD or control), respectively (<xref ref-type="fig" rid="F7">Fig. 7a-c</xref>). Our co-methylation network analysis also revealed modules associated with specific pathological subgroup/subtypes in FTLD1 and FTLD2 networks (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref>, Online Resource). In a few cases, opposite effect directions were shown in one subgroup/subtype compared to another (e.g., midnightblue and salmon modules in FTLD1 TDPA vs TDPC, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4a</xref>; and turquoise module in FTLD2 TDP vs Tau, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4b</xref>; Online Resource). More detailed identification of subtype-specific DNA methylation signatures warrants further investigation in future studies.</p><p id="P31">We also tested for correlations with additional disease-related traits as available for FTLD1, FTLD2, and FTLD3. We found associations between FTLD-associated co-methylation modules and disease duration as well as with macroscopic and/or microscopic measures of atrophy/neurodegeneration in the frontal and temporal lobes (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4a-b</xref>, Online Resource). Two out of the ten modules associated with the disease status in FTLD3 were also associated with tau pathological burden (Braak stage, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4c</xref>, Online Resource).</p><p id="P32">To assess replication of FTLD-associated co-methylation modules across datasets, we then ran preservation analysis for each dataset against each of the networks. We found that most of the FTLD-associated co-methylation modules were indeed moderately to highly preserved (Z-summary &gt; 2) in at least one of the other two datasets (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 5</xref>, Online Resource), further supporting their relevance to FTLD regardless of the pathological subgroup/subtype. Exceptions to this were observed only for the FTLD1 brown, darkturquoise and grey60, and the FTLD2 darkorange2 modules, which seem to be perturbed in the other two datasets.</p></sec><sec id="S19"><title>Genes that compose FTLD-associated co-methylation modules are involved in transcription regulation, phosphorylation, the ubiquitin system and actin cytoskeleton dynamics</title><p id="P33">We then performed functional enrichment analysis to investigate which gene ontologies were shared across the three FTLD co-methylation networks. We found significant enrichment of terms related with transcription regulation (e.g., “DNA-binding transcription factor binding”), phosphorylation (“protein serine/threonine/tyrosine kinase activity”), the ubiquitin system (e.g., “ubiquitin protein ligase activity”), and actin cytoskeleton dynamics (e.g., “actin filament binding”). This was observed across the three co-methylation networks and across different modules of each network (<xref ref-type="fig" rid="F8">Fig. 8</xref>). Dysregulation of all these processes had been previously linked to FTLD [<xref ref-type="bibr" rid="R68">68</xref>], and our findings now support a role for DNA methylation as a mechanism involved in such dysregulation.</p></sec><sec id="S20"><title>FTLD-associated modules are enriched for genes relevant for pyramidal neurons and endothelial cells across all three co-methylation networks</title><p id="P34">We also aimed to elucidate whether the genes that compose FTLD-associated comethylation modules are relevant for specific brain cell-types. Across the three networks (FTLD1, FTLD2 and FTLD3), we found significant enrichments for pyramidal neurons and endothelial/mural cells (<xref ref-type="fig" rid="F9">Fig. 9</xref>), suggesting these cell types are consistently affected by the DNA methylation changes in FTLD regardless of the pathological subgroup/subtype. Previous studies with pathological assessment, as well as transcriptomic analysis in FTLD brain tissue, support changes in these cell types in FTLD [<xref ref-type="bibr" rid="R24">24</xref>–<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R63">63</xref>]. Additionally, in the FTLD1 and the FTLD3 networks, we found signatures with an overrepresentation of oligodendrocyte markers. Of note, FTLD3 is composed of PSP cases, which, unlike the other FTLD groups studied here, is known to present with pathological accumulation of tau in the oligodendrocytes [<xref ref-type="bibr" rid="R84">84</xref>]. The FTLD3 network was also enriched for microglia and interneurons.</p></sec><sec id="S21"><title><italic>OTUD4</italic> and other top meta-analysis loci are co-methylated in all three networks</title><p id="P35">We then examined whether the 11 EWAS meta-analysis top loci (FDR p &lt; 0.10) were present (Supplementary Table S2, Online Resource) in the co-methylation networks and whether any co-methylation modules were enriched for such loci (Supplementary Table S3, Online Resource). Notably, the top meta-analysis hit in <italic>OTUD4</italic> was present in all three networks (FTLD1 – brown, FTLD2 – blue, and FTLD3 – blue modules), and was always co-methylated with the CpG annotated to <italic>CEBPZ</italic> (Supplementary Table S3, Online Resource). These modules showed a significant enrichment for the top EWAS meta-analysis loci [Fisher’s exact test, FTLD1 – brown odds ratio (OR) = 14.9, p = 0.003; FTLD2 – blue OR = 10.6, p = 0.007; FTLD3 – blue OR = 8.0, p = 0.017). We therefore decided to further investigate similarities across these three modules (FTLD1 – brown, FTLD2 – blue, and FTLD3 – blue), which will henceforth be referred to as “OTUD4-modules”.</p><p id="P36">It is of note that only eight CpGs were shared across the three “OTUD4-modules”, two of which - cg21028777 in <italic>OTUD4</italic> and cg07695590 in <italic>CEBPZ -</italic> correspond to top EWAS meta-analysis loci (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6</xref>, Online Resource), highlighting their importance across the FTLD subgroups/subtypes. All three “OTUD4-modules” were inversely related with the disease status, i.e., lower levels of methylation in CpGs composing these modules are associated with increased risk of FTLD (<xref ref-type="fig" rid="F7">Fig. 7</xref>; FTLD1 – brown r=-0.89, p = 2×10<sup>-8</sup>; FTLD2 – blue r=-0.75, p = 8×10<sup>-9</sup>; and FTLD3 – blue r=-0.89, p = 3×10<sup>-54</sup>). FTLD2 blue was also inversely associated with the severity of neuronal loss in the frontal cortex (r=-0.48, p=0.001, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4b</xref>, Online Resource). Although not reaching statistical significance after accounting for multiple testing corrections, a similar trend was observed with the severity of neuronal loss in the temporal cortex for FTLD2 blue (r=-0.46, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4b</xref>, Online Resource) as well as for FTLD1 brown in both frontal and temporal cortices (r=-0.29 n.s., and r=-0.63 p = 0.001, respectively, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4a</xref>, Online Resource). These findings further support the relevance of these signatures enriched for top EWAS meta-analysis loci, including CpGs in <italic>OTUD4</italic> and <italic>CEBPZ,</italic> in disease progression/severity.</p><p id="P37">Previous studies have shown that OTUD4 [<xref ref-type="bibr" rid="R20">20</xref>], tau [<xref ref-type="bibr" rid="R5">5</xref>], TDP-43 and a growing number of additional FTLD-related RNA-binding proteins [<xref ref-type="bibr" rid="R10">10</xref>] play an important role in the biology of stress granules. We therefore investigated whether stress granules proteins and OTUD4 protein interactors were present in the “OTUD4-modules”. Indeed, many genes encoding for such proteins were represented in these modules, including several genes associated with genetic FTLD risk such as <italic>MAPT</italic> (encoding for tau), present across the three <italic>“OTUD4-</italic>modules”, and <italic>FUS,</italic> present in FTLD3-blue (Supplementary Tables S4 and S5, Online Resource). The same was true for many hnRNPs, such as <italic>HNRNPA1, HNRNPC,</italic> and <italic>HNRNPUL1,</italic> which are present in the “OTUD4-modules” and are OTUD4 protein interactors (Supplementary Tables S4 and S5, Online Resource). These hnRNPs are also known targets of the transcription factor <italic>CEBPZ</italic> (as described by Ma’ayan et al. [<xref ref-type="bibr" rid="R65">65</xref>]), which is also a top EWAS meta-analysis loci and is co-methylated with <italic>OTUD4</italic> across the networks.</p><p id="P38">We also identified the hub genes in the three “OTUD4-modules” (i.e., the most interconnected genes within the module). These were <italic>ADCY1, TLE6</italic> and <italic>GDAP1</italic> for FTLD1-brown, FTLD2-blue and FTLD3-blue, respectively (Supplementary Table S4, Online Resource). Of note and highly relevant for FTLD, <italic>ADCY1</italic> has been found to be implicated in learning, memory, and behaviour [<xref ref-type="bibr" rid="R71">71</xref>]. The importance of <italic>TLE6 to</italic> brain related disease is supported through its association with bipolar disorder [<xref ref-type="bibr" rid="R21">21</xref>], and mutations in <italic>GDAP1</italic> cause inherited peripheral neuropathies [<xref ref-type="bibr" rid="R61">61</xref>].</p></sec><sec id="S22"><title>“OTUD4-modules” implicate glutamatergic synapse and pyramidal neurons</title><p id="P39">More detailed gene ontology enrichment of “OTUD4-modules” once again highlighted transcriptional regulation and the ubiquitin system, as well as nuclear speck, synapse (particularly glutamatergic synapse), and axon development (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 7</xref>, Online Resource). All three meta-hit modules showed an enrichment for pyramidal neurons and the FTLD3 blue module additionally showed an enrichment for oligodendrocytes (<xref ref-type="fig" rid="F9">Fig. 9</xref>). Further supporting the importance of <italic>OTUD4</italic> and <italic>CEBPZ</italic> in glutamatergic cells, in the normal brain (human and mouse) these genes show the highest expression in glutamatergic neurons and/or cortical and hippocampal pyramidal and granule cell layers (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 8-9</xref>, Online Resource).</p><p id="P40">Using gene expression data and derived cellular proportions from Hasan et al. [<xref ref-type="bibr" rid="R30">30</xref>], we observed a positive relationship between both <italic>OTUD4</italic> and <italic>CEBPZ</italic> expression and proportions of excitatory neurons in controls and FTLD-TDP type A (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 10</xref>, Online Resource). This finding further supports the relevance of <italic>OTUD4</italic> and <italic>CEBPZ</italic> in excitatory glutamatergic neurons. However, that relationship is perturbed in FTLD-TDP type C (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 10</xref>, Online Resource), which could suggest higher expression of these genes by fewer surviving excitatory neurons and/or higher expression by other cell type(s).</p></sec></sec><sec id="S23" sec-type="discussion"><title>Discussion</title><p id="P41">We have conducted,to our knowledge, the first FTLD EWAS meta-analysis utilizing three independent cohorts and incorporating results from 234 brain donors. We identified two differentially methylated CpGs shared across a range of FTLD subgroups (FTLD-TDP and FTLD-tau) and corresponding subtypes, which map to <italic>OTUD4</italic> and <italic>NFATC1.</italic> Systems biology approaches such as co-methylation network analysis are powerful methodologies for identifying pathways and networks which may be more relevant to disease pathophysiology than individual genes. We therefore performed a co-methylation network analysis in each of the independent cohorts and identified modules associated with the FTLD disease status and FTLD-related traits. Interestingly, <italic>CEBPZ</italic> always clustered with <italic>OTUD4,</italic> and the <italic>“OTUD4</italic>-modules” were enriched for meta-analysis top loci in each of the three independent cohorts. Using functional and cell-type enrichment analysis of modules of interest, we identified several biological processes with relevance to FTLD pathology, including the ubiquitin system, RNA granule formation and glutamatergic synaptic signalling, which we discuss below. It is of note that none of the loci identified in our meta-analysis match with neuropathology-associated loci identified in large AD studies [<xref ref-type="bibr" rid="R72">72</xref>, <xref ref-type="bibr" rid="R74">74</xref>, <xref ref-type="bibr" rid="R89">89</xref>], therefore supporting the hypothesis that molecular changes in these loci reflect shared disease biology aspects of FTLD subgroups/subtypes rather than a mere downstream consequence of neurodegeneration.</p><p id="P42">The <italic>OTUD4</italic> gene encodes the protein OTUD domain-containing protein 4, a deubiquitinating enzyme [<xref ref-type="bibr" rid="R54">54</xref>]. Mutations in this gene are associated with Gordon Holmes syndrome, which is characterised by ataxia and hypogonadotropism [<xref ref-type="bibr" rid="R48">48</xref>]. Interestingly, a combination of mutations in <italic>OTUD4</italic> along with mutations in <italic>RNF216,</italic> which codes for a ubiquitin ligase, was also found to result in dementia [<xref ref-type="bibr" rid="R48">48</xref>]. The protein is known to have roles in modulating inflammatory signalling [<xref ref-type="bibr" rid="R91">91</xref>] and in the alkylation damage response [<xref ref-type="bibr" rid="R90">90</xref>], and has more recently been demonstrated to interact with RNA binding proteins (RBPs), including TDP-43 (which aggregates in FTLD-TDP), which are important in the functioning of neuronal RNA granules and stress granules [<xref ref-type="bibr" rid="R18">18</xref>]. RNA granules are structures which facilitate the translocation and storage of mRNAs [<xref ref-type="bibr" rid="R37">37</xref>], whilst stress granules are formed when cellular stressors such as oxidative stress are present, possibly as a mechanism to reversibly block translation initiation until the stress has been removed [<xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R35">35</xref>]. Notably, similarly to TDP-43 [<xref ref-type="bibr" rid="R6">6</xref>], OTUD4 was shown to be important in the correct formation of stress granules [<xref ref-type="bibr" rid="R20">20</xref>]. Indeed, there is much evidence as to the importance of the ubiquitin system in the functioning of stress granules [<xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R77">77</xref>]. The hypomethylation of the 5’UTR region of <italic>OTUD4</italic> (cg21028777), which was observed as the top hit from the FTLD EWAS meta-analysis, and the inclusion of this CpG in three modules where decreased methylation was associated with increased risk of FTLD indicates that decreased methylation of this gene might be involved in the pathogenesis of FTLD. Further supporting these findings, the <italic>OTUD4 gene</italic> and protein expression levels are dysregulated in FTLD [<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R82">82</xref>].</p><p id="P43">Also supporting the importance of the role of ubiquitination and granule formation are the results from the functional enrichment analysis of the three network modules containing <italic>OTUD4,</italic> which revealed an overrepresentation of terms relating to the ubiquitin system. All three meta-hit modules contained terms such as “ubiquitin protein ligase activity”, the FTLD2-blue module also showed enrichment of the GO term “ribonucleoprotein granule”, indicating that other genes in this module might also have processes relevant to granule formation, as with the meta-hit <italic>OTUD4.</italic> Ubiquitin signalling is well described as a process implicated in neurodegenerative disease pathology, and several genes involved in ubiquitin and ubiquitin binding processes are known to be mutated/contain risk alleles in multiple neurodegenerative diseases, including FTD [<xref ref-type="bibr" rid="R68">68</xref>].</p><p id="P44">Ontology terms enriched in our functional analysis of FTLD-associated modules also include many relating to regulation of transcription such as “DNA-binding transcription factor binding” and “transcription coregulator activity”. Another meta-analysis top loci was annotated to the <italic>CEBPZ gene,</italic> which encodes the CCAAT Enhancer Binding Protein Zeta, a transcription factor implicated in cellular response to environmental stimuli through transcriptional processes that regulate heat shock factors, including HSP70 [<xref ref-type="bibr" rid="R47">47</xref>]. HSP70 is a heat-shock protein involved in several protein folding processes, including the refolding of aggregated proteins [<xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R62">62</xref>]. Furthermore, HSP70 has been shown to have a role in the prevention of build-up of misfolded proteins in stress granules [<xref ref-type="bibr" rid="R49">49</xref>]. Interestingly, a CpG in <italic>PFDN6</italic> was the top-most differentially methylated CpG in the FTLD3 (FTLD-tau) EWAS. This gene encodes for the subunit 6 of prefoldin, which is a co-chaperone of HSP70, regulates the correct folding of proteins and is involved in the proper assembly of cytoskeletal proteins [<xref ref-type="bibr" rid="R44">44</xref>]. Prefoldin proteins themselves have also been associated with neurodegenerative disease pathology [<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R75">75</xref>].</p><p id="P45">Our functional enrichment analysis of the “OTUD4-modules”, FTLD1-brown, FTLD2-blue and FTLD3-blue, showed that these modules were enriched for GO terms (for cellular component) relating to synapses, including “synaptic membrane”, “asymmetric synapse”, “postsynaptic density”, and “glutamatergic synapse”. Cell-type enrichment analysis revealed that these three modules were also significantly enriched for markers of pyramidal/glutamatergic cells. These findings were further substantiated with expression patterns of <italic>OTUD4</italic> and <italic>CEBPZ</italic> single-nuclei and mouse expression data. Glutamate, which is the most abundant excitatory neurotransmitter in the human brain [<xref ref-type="bibr" rid="R92">92</xref>], is typically associated with memory, learning and other higher cognitive functions [<xref ref-type="bibr" rid="R12">12</xref>], and has also been implicated in neurodegeneration [<xref ref-type="bibr" rid="R58">58</xref>]. The contribution of neurotransmitter deficits, and specifically, changes in glutamate and glutamate signalling have been described in FTD [<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R33">33</xref>, <xref ref-type="bibr" rid="R56">56</xref>]. DNA methylation has previously been suggested to be an important regulator of glutamatergic synaptic scaling (also known as homeostatic synaptic plasticity), with demethylation found to be associated with increased glutamatergic synapse strength in cultured neurons [<xref ref-type="bibr" rid="R52">52</xref>], we here find evidence supporting disruption of such processes in FTLD. Homeostatic synaptic plasticity has been linked to neurodegeneration, possibly with loss of function due to pathogenesis, or through an increase as a mechanism to preserve function despite neurodegenerative deficits [<xref ref-type="bibr" rid="R60">60</xref>]. There is a known link between RNA granule formation and synapse plasticity; with RNA-binding protein function known to be particularly important. This has been proposed to be dysregulated in FTLD, whereby mutations in the genes encoding for TDP-43 and FUS lead to dysregulated granule formation dynamics and consequent disturbances in mRNA translation and synaptic function [<xref ref-type="bibr" rid="R45">45</xref>, <xref ref-type="bibr" rid="R70">70</xref>]. Moreover, the levels of known OTUD4 protein interactor FMRP are regulated by ubiquitination in response to stimulation by the metabotropic glutamate receptor [<xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R57">57</xref>], and this is involved in the regulation of synaptic plasticity, providing another possible link between separate findings in our study.</p><p id="P46">The <italic>NFATC1</italic> gene, which was also identified as an FTLD-associated loci in the EWAS metaanalysis, encodes the nuclear factor of activated T cells 1, and belongs to the NFAT family of activity-dependent transcription factors. In the nervous system, the NFAT family has been shown to play a regulatory role in neuronal excitability, axonal growth, synaptic plasticity, and neuronal survival [<xref ref-type="bibr" rid="R80">80</xref>]. Aberrant NFAT-related signalling has been reported in AD, and NFAT1 seems to be selectively activated early in cognitive decline [<xref ref-type="bibr" rid="R1">1</xref>], supporting its possible involvement in the pathogenesis of neurodegenerative diseases/dementias.</p><p id="P47">As is the case with any other genome-wide DNA methylation study, there are key limitations. First, by studying post-mortem tissue, i.e., the end stage of the disease, causality cannot be elucidated. Second, because FTLD is heterogeneous, comprising several pathological subgroups and subtypes, and given the relatively small sample size per subtype, this might have hampered the identification of additional DNA methylation alterations, especially subtype-specific variation. Notwithstanding, we focused on the shared DNA methylation variation across FTLD subgroups/subtypes, and we used independent and complementary analytical approaches (EWAS followed by meta-analysis, and comethylation network analysis followed by preservation analysis) and datasets, which identified concordant results and consistently identified the involvement of <italic>OTUD4</italic> and related genes in FTLD.</p><p id="P48">In summary, this study identified genome-wide DNA methylation changes in post-mortem frontal cortex tissue of FTLD subjects, highlighting new FTLD-associated loci, and implicated DNA methylation as a mechanism involved in the dysregulation of important processes such as ubiquitin and glutamatergic signalling in FTLD. Our findings increase the understanding of the biology of FTLD and role of DNA methylation its pathophysiology, pointing towards new avenues that could be explored for therapeutic development.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>supplementary figures</label><media xlink:href="EMS156182-supplement-supplementary_figures.pdf" mimetype="application" mime-subtype="pdf" id="d28aAdEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S24"><title>Acknowledgements</title><p>The authors would like to thank UCL Genomics centre for advice and processing of the EPIC arrays for the FTLD1 cohort. The authors would also like to acknowledge the Queen Square Brain Bank (London, UK), and the Dutch Brain Bank, Netherlands Institute for Neuroscience (Amsterdam, Netherlands) for providing brain tissues from FTLD cases and controls. The Queen Square Brain Bank is supported by the Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology. KF is supported by the Medical Research Council (MR/N013867/1). MM is supported by a grant from the Multiple System Atrophy Trust awarded to CB. CB is supported by Alzheimer’s Research UK (ARUK-RF2019B-005) and the Multiple System Atrophy Trust. JH, RH, and TR are supported by NIH NIA R56-AG055824 and U01-AG068880, and NIH NINDS U54NS123743.</p></ack><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul</surname><given-names>HM</given-names></name><name><surname>Furman</surname><given-names>JL</given-names></name><name><surname>Sama</surname><given-names>MA</given-names></name><name><surname>Mathis</surname><given-names>DM</given-names></name><name><surname>Norris</surname><given-names>CM</given-names></name></person-group><article-title>NFATs and Alzheimer’s Disease</article-title><source>Mol Cell Pharmacol</source><year>2010</year><volume>2</volume><fpage>7</fpage><pub-id pub-id-type="pmcid">PMC2855852</pub-id><pub-id pub-id-type="pmid">20401186</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldana</surname><given-names>Bl</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jensen</surname><given-names>P</given-names></name><name><surname>Chandrasekaran</surname><given-names>A</given-names></name><name><surname>Christensen</surname><given-names>SK</given-names></name><name><surname>Nielsen</surname><given-names>TT</given-names></name><name><surname>Nielsen</surname><given-names>JE</given-names></name><name><surname>Hyttel</surname><given-names>P</given-names></name><name><surname>Larsen</surname><given-names>MR</given-names></name><name><surname>Waagepetersen</surname><given-names>HS</given-names></name><name><surname>Freude</surname><given-names>KK</given-names></name></person-group><article-title>Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia</article-title><source>Mol Brain</source><year>2020</year><volume>13</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmcid">PMC7491073</pub-id><pub-id pub-id-type="pmid">32928252</pub-id><pub-id pub-id-type="doi">10.1186/s13041-020-00658-6</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Serie</surname><given-names>DJ</given-names></name><name><surname>Strickland</surname><given-names>SL</given-names></name><name><surname>Burgess</surname><given-names>JD</given-names></name><name><surname>Koga</surname><given-names>S</given-names></name><name><surname>Younkin</surname><given-names>CS</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Malphrus</surname><given-names>KG</given-names></name><name><surname>Lincoln</surname><given-names>SJ</given-names></name><name><surname>Alamprese</surname><given-names>M</given-names></name><etal/></person-group><article-title>Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy</article-title><source>Acta Neuropathol</source><year>2018</year><volume>136</volume><fpage>709</fpage><pub-id pub-id-type="pmcid">PMC6208732</pub-id><pub-id pub-id-type="pmid">30136084</pub-id><pub-id pub-id-type="doi">10.1007/s00401-018-1900-5</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Aryee</surname><given-names>MJ</given-names></name><name><surname>Jaffe</surname><given-names>AE</given-names></name><name><surname>Corrada-Bravo</surname><given-names>H</given-names></name><name><surname>Ladd-Acosta</surname><given-names>C</given-names></name><name><surname>Feinberg</surname><given-names>AP</given-names></name><name><surname>Hansen</surname><given-names>KD</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name></person-group><article-title>Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays</article-title><source>Bioinformatics</source><year>2014</year><pub-id pub-id-type="doi">10.1093/bioinformatics/btu049</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ash</surname><given-names>PEA</given-names></name><name><surname>Lei</surname><given-names>S</given-names></name><name><surname>Shattuck</surname><given-names>J</given-names></name><name><surname>Boudeau</surname><given-names>S</given-names></name><name><surname>Carlomagno</surname><given-names>Y</given-names></name><name><surname>Medalla</surname><given-names>M</given-names></name><name><surname>Mashimo</surname><given-names>BL</given-names></name><name><surname>Socorro</surname><given-names>G</given-names></name><name><surname>Al-Mohanna</surname><given-names>LFA</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Öztürk</surname><given-names>MM</given-names></name><etal/></person-group><article-title>TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><volume>118</volume><elocation-id>e2014188118</elocation-id><pub-id pub-id-type="pmcid">PMC7936275</pub-id><pub-id pub-id-type="pmid">33619090</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2014188118</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aulas</surname><given-names>A</given-names></name><name><surname>Stabile</surname><given-names>S</given-names></name><name><surname>vande Velde</surname><given-names>C</given-names></name></person-group><article-title>Endogenous TDP-43, but notFUS, contributes to stress granule assembly via G3BP</article-title><source>Mol Neurodegener</source><year>2012</year><fpage>7</fpage><pub-id pub-id-type="pmcid">PMC3502460</pub-id><pub-id pub-id-type="pmid">23092511</pub-id><pub-id pub-id-type="doi">10.1186/1750-1326-7-54</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakken</surname><given-names>TE</given-names></name><name><surname>Jorstad</surname><given-names>NL</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Lake</surname><given-names>BB</given-names></name><name><surname>Tian</surname><given-names>W</given-names></name><name><surname>Kalmbach</surname><given-names>BE</given-names></name><name><surname>Crow</surname><given-names>M</given-names></name><name><surname>Hodge</surname><given-names>RD</given-names></name><name><surname>Krienen</surname><given-names>FM</given-names></name><name><surname>Sorensen</surname><given-names>SA</given-names></name><name><surname>Eggermont</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparative cellular analysis of motor cortex in human, marmoset and mouse</article-title><source>Nature</source><year>2021</year><volume>598</volume><fpage>111</fpage><lpage>119</lpage><comment>2021 598:7879</comment><pub-id pub-id-type="pmcid">PMC8494640</pub-id><pub-id pub-id-type="pmid">34616062</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-03465-8</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balduzzi</surname><given-names>S</given-names></name><name><surname>Rücker</surname><given-names>G</given-names></name><name><surname>Schwarzer</surname><given-names>G</given-names></name></person-group><article-title>Statistics in practice How to perform a metaanalysis with R: a practical tutorial</article-title><source>Evid Based Ment Health</source><year>2019</year><volume>22</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">31563865</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banzhaf-Strathmann</surname><given-names>J</given-names></name><name><surname>Claus</surname><given-names>R</given-names></name><name><surname>Mücke</surname><given-names>O</given-names></name><name><surname>Rentzsch</surname><given-names>K</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>de Deyn</surname><given-names>PP</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Plass</surname><given-names>C</given-names></name><name><surname>Edbauer</surname><given-names>D</given-names></name></person-group><article-title>Promoter DNA methylation regulates progranulin expression and is altered in FTLD</article-title><source>Acta Neuropathol Commun</source><year>2013</year><volume>1</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmcid">PMC3893557</pub-id><pub-id pub-id-type="pmid">24252647</pub-id><pub-id pub-id-type="doi">10.1186/2051-5960-1-16</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baradaran-Heravi</surname><given-names>Y</given-names></name><name><surname>van Broeckhoven</surname><given-names>C</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name></person-group><article-title>Stress granule mediated protein aggregation and underlying gene defects in the FTD-ALS spectrum</article-title><source>Neurobiol Dis</source><year>2020</year><fpage>134</fpage><pub-id pub-id-type="pmid">31626953</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettencourt</surname><given-names>C</given-names></name><name><surname>Foti</surname><given-names>SC</given-names></name><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Botia</surname><given-names>J</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Warner</surname><given-names>TT</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Balazs</surname><given-names>R</given-names></name><name><surname>Viré</surname><given-names>E</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name></person-group><article-title>White matter DNA methylation profiling reveals deregulation of HIP1, LMAN2, MOBP, and other loci in multiple system atrophy</article-title><source>Acta Neuropathol</source><year>2020</year><volume>139</volume><fpage>135</fpage><pub-id pub-id-type="pmcid">PMC6942018</pub-id><pub-id pub-id-type="pmid">31535203</pub-id><pub-id pub-id-type="doi">10.1007/s00401-019-02074-0</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bliss</surname><given-names>TVP</given-names></name><name><surname>Collingridge</surname><given-names>GL</given-names></name></person-group><article-title>A synaptic model of memory: long-term potentiation in the hippocampus</article-title><year>1993</year><pub-id pub-id-type="pmid">8421494</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botia</surname><given-names>JA</given-names></name><name><surname>Vandrovcova</surname><given-names>J</given-names></name><name><surname>Forabosco</surname><given-names>P</given-names></name><name><surname>Guelfi</surname><given-names>S</given-names></name><name><surname>D’Sa</surname><given-names>K</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Ryten</surname><given-names>M</given-names></name><name><surname>Weale</surname><given-names>ME</given-names></name><name><surname>Ramasamy</surname><given-names>A</given-names></name><name><surname>Trabzuni</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Walker</surname><given-names>R</given-names></name></person-group><article-title>An additional k-means clustering step improves the biological features of WGCNA gene co-expression networks</article-title><source>BMCSyst Biol</source><year>2017</year><pub-id pub-id-type="pmcid">PMC5389000</pub-id><pub-id pub-id-type="pmid">28403906</pub-id><pub-id pub-id-type="doi">10.1186/s12918-017-0420-6</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowles</surname><given-names>KR</given-names></name><name><surname>Silva</surname><given-names>MC</given-names></name><name><surname>Whitney</surname><given-names>K</given-names></name><name><surname>Bertucci</surname><given-names>T</given-names></name><name><surname>Garza</surname><given-names>JC</given-names></name><name><surname>Boles</surname><given-names>NC</given-names></name><name><surname>Strang</surname><given-names>KH</given-names></name><name><surname>Mahali</surname><given-names>S</given-names></name><name><surname>Marsh</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Pugh</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Glutamatergic dysfunction precedes neuron loss in cerebral organoids with MAPT mutation</article-title><source>bioRxiv</source><year>2021</year><elocation-id>2021.02.03.429623</elocation-id><pub-id pub-id-type="pmcid">PMC8635409</pub-id><pub-id pub-id-type="pmid">34314701</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2021.07.003</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>AL</given-names></name><name><surname>Wilkins</surname><given-names>OG</given-names></name><name><surname>Keuss</surname><given-names>MJ</given-names></name><name><surname>Hill</surname><given-names>SE</given-names></name><name><surname>Zanovello</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Bampton</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>FCY</given-names></name><name><surname>Masino</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>YA</given-names></name><name><surname>Bryce-Smith</surname><given-names>S</given-names></name><etal/></person-group><article-title>TDP-43 loss and ALS-risk SNPs drive missplicing and depletion of UNC13A</article-title><source>Nature</source><year>2022</year><volume>603</volume><issue>7899</issue><fpage>131</fpage><lpage>137</lpage><comment>2022 603</comment><pub-id pub-id-type="pmcid">PMC8891020</pub-id><pub-id pub-id-type="pmid">35197628</pub-id><pub-id pub-id-type="doi">10.1038/s41586-022-04436-3</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>JR</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><article-title>Eukaryotic stress granules: the ins and outs of translation</article-title><source>Mol Cell</source><year>2009</year><volume>36</volume><fpage>932</fpage><lpage>941</lpage><pub-id pub-id-type="pmcid">PMC2813218</pub-id><pub-id pub-id-type="pmid">20064460</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2009.11.020</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Mackenzie</surname><given-names>IRA</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Hatanpaa</surname><given-names>KJ</given-names></name><name><surname>White</surname><given-names>CL</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Grinberg</surname><given-names>LT</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><etal/></person-group><article-title>Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration</article-title><source>Acta Neuropathol</source><year>2007</year><volume>114</volume><fpage>5</fpage><lpage>22</lpage><pub-id pub-id-type="pmcid">PMC2827877</pub-id><pub-id pub-id-type="pmid">17579875</pub-id><pub-id pub-id-type="doi">10.1007/s00401-007-0237-2</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos-Melo</surname><given-names>D</given-names></name><name><surname>Hawley</surname><given-names>ZCE</given-names></name><name><surname>Droppelmann</surname><given-names>CA</given-names></name><name><surname>Strong</surname><given-names>MJ</given-names></name></person-group><article-title>The Integral Role of RNA in Stress Granule Formation and Function</article-title><source>Front Cell Dev Biol</source><year>2021</year><volume>9</volume><fpage>808</fpage><pub-id pub-id-type="pmcid">PMC8173143</pub-id><pub-id pub-id-type="pmid">34095105</pub-id><pub-id pub-id-type="doi">10.3389/fcell.2021.621779</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Won</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>AY</given-names></name><name><surname>Lowe</surname><given-names>JK</given-names></name><name><surname>Wojta</surname><given-names>K</given-names></name><name><surname>Yokoyama</surname><given-names>JS</given-names></name><name><surname>Bensimon</surname><given-names>G</given-names></name><name><surname>Leigh</surname><given-names>PN</given-names></name><name><surname>Payan</surname><given-names>C</given-names></name><name><surname>Shatunov</surname><given-names>A</given-names></name><etal/></person-group><article-title>Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases</article-title><source>Mol Neurodegener</source><year>2018</year><volume>13</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmcid">PMC6083608</pub-id><pub-id pub-id-type="pmid">30089514</pub-id><pub-id pub-id-type="doi">10.1186/s13024-018-0270-8</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Schwintzer</surname><given-names>L</given-names></name><name><surname>Vinopal</surname><given-names>S</given-names></name><name><surname>Roca</surname><given-names>EA</given-names></name><name><surname>Sylvester</surname><given-names>M</given-names></name><name><surname>Oprisoreanu</surname><given-names>AM</given-names></name><name><surname>Schoch</surname><given-names>S</given-names></name><name><surname>Bradke</surname><given-names>F</given-names></name><name><surname>Broemer</surname><given-names>M</given-names></name></person-group><article-title>New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules</article-title><source>J Cell Sci</source><year>2019</year><fpage>132</fpage><pub-id pub-id-type="pmcid">PMC6602300</pub-id><pub-id pub-id-type="pmid">31138677</pub-id><pub-id pub-id-type="doi">10.1242/jcs.229252</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dempster</surname><given-names>EL</given-names></name><name><surname>Pidsley</surname><given-names>R</given-names></name><name><surname>Schalkwyk</surname><given-names>LC</given-names></name><name><surname>Owens</surname><given-names>S</given-names></name><name><surname>Georgiades</surname><given-names>A</given-names></name><name><surname>Kane</surname><given-names>F</given-names></name><name><surname>Kalidindi</surname><given-names>S</given-names></name><name><surname>Picchioni</surname><given-names>M</given-names></name><name><surname>Kravariti</surname><given-names>E</given-names></name><name><surname>Toulopoulou</surname><given-names>T</given-names></name><name><surname>Murray</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><fpage>4786</fpage><lpage>4796</lpage><pub-id pub-id-type="pmcid">PMC3221539</pub-id><pub-id pub-id-type="pmid">21908516</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddr416</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Jafari</surname><given-names>N</given-names></name><name><surname>Kibbe</surname><given-names>WA</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>SM</given-names></name></person-group><article-title>Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis</article-title><source>BMC Bioinformatics</source><year>2010</year><volume>11</volume><pub-id pub-id-type="pmcid">PMC3012676</pub-id><pub-id pub-id-type="pmid">21118553</pub-id><pub-id pub-id-type="doi">10.1186/1471-2105-11-587</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>R</given-names></name><name><surname>Hernandez</surname><given-names>DG</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Rohrer</surname><given-names>JD</given-names></name><name><surname>Ramasamy</surname><given-names>A</given-names></name><name><surname>Kwok</surname><given-names>JBJ</given-names></name><name><surname>Dobson-Stone</surname><given-names>C</given-names></name><name><surname>Brooks William</surname><given-names>SBS</given-names></name><name><surname>Schofield</surname><given-names>PR</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Hodges</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Frontotemporal dementia and its subtypes: a genome-wide association study</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><fpage>686</fpage><lpage>699</lpage><pub-id pub-id-type="pmcid">PMC4112126</pub-id><pub-id pub-id-type="pmid">24943344</pub-id><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70065-1</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>I</given-names></name></person-group><article-title>Neurons and their dendrites in frontotemporal dementia</article-title><source>Dement GeriatrCogn Disord</source><year>1999</year><volume>10</volume><issue>Suppl 1</issue><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">10436342</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fyfe</surname><given-names>I</given-names></name></person-group><article-title>Surprise neurovascular dysfunction in frontotemporal dementia</article-title><source>Nature Reviews Neurology</source><year>2022</year><volume>18</volume><issue>9</issue><fpage>509</fpage><comment>2022 18</comment><pub-id pub-id-type="pmid">35945458</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerrits</surname><given-names>E</given-names></name><name><surname>Giannini</surname><given-names>LAA</given-names></name><name><surname>Brouwer</surname><given-names>N</given-names></name><name><surname>Melhem</surname><given-names>S</given-names></name><name><surname>Seilhean</surname><given-names>D</given-names></name><name><surname>le Ber</surname><given-names>I</given-names></name><name><surname>Kamermans</surname><given-names>A</given-names></name><name><surname>Kooij</surname><given-names>G</given-names></name><name><surname>de Vries</surname><given-names>HE</given-names></name><name><surname>Boddeke</surname><given-names>EWGM</given-names></name><name><surname>Seelaar</surname><given-names>H</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name><name><surname>Eggen</surname><given-names>BJL</given-names></name></person-group><article-title>Neurovascular dysfunction in GRN-associated frontotemporal dementia identified by single-nucleus RNA sequencing of human cerebral cortex</article-title><source>Nature Neuroscience</source><year>2022</year><volume>25</volume><issue>8</issue><fpage>1034</fpage><lpage>1048</lpage><comment>2022 25</comment><pub-id pub-id-type="pmid">35879464</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>JS</given-names></name><name><surname>Farmer</surname><given-names>JM</given-names></name><name><surname>Wood</surname><given-names>EM</given-names></name><name><surname>Johnson</surname><given-names>JK</given-names></name><name><surname>Boxer</surname><given-names>A</given-names></name><name><surname>Neuhaus</surname><given-names>J</given-names></name><name><surname>Lomen-Hoerth</surname><given-names>C</given-names></name><name><surname>Wilhelmsen</surname><given-names>KC</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name></person-group><article-title>Comparison of family histories in FTLD subtypes and related tauopathies</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1817</fpage><lpage>1819</lpage><pub-id pub-id-type="pmid">16344531</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundman</surname><given-names>J</given-names></name><name><surname>Spencer</surname><given-names>B</given-names></name><name><surname>Sarsoza</surname><given-names>F</given-names></name><name><surname>Rissman Id</surname><given-names>RA</given-names></name></person-group><article-title>Transcriptome analyses reveal tau isoform-driven changes in transposable element and gene expression</article-title><pub-id pub-id-type="pmcid">PMC8480850</pub-id><pub-id pub-id-type="pmid">34587152</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0251611</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haapasalo</surname><given-names>A</given-names></name><name><surname>Vermeiren</surname><given-names>Y</given-names></name><name><surname>Linden</surname><given-names>R</given-names></name><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Benussi</surname><given-names>A</given-names></name><name><surname>Alberici</surname><given-names>A</given-names></name><name><surname>Buratti</surname><given-names>E</given-names></name><name><surname>Ghidoni</surname><given-names>R</given-names></name><name><surname>Gardoni</surname><given-names>F</given-names></name><name><surname>di Luca</surname><given-names>M</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name></person-group><article-title>Toward a Glutamate Hypothesis of Frontotemporal Dementia</article-title><year>2019</year><pub-id pub-id-type="pmcid">PMC6449454</pub-id><pub-id pub-id-type="pmid">30983965</pub-id><pub-id pub-id-type="doi">10.3389/fnins.2019.00304</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>R</given-names></name><name><surname>Humphrey</surname><given-names>J</given-names></name><name><surname>Bettencourt</surname><given-names>C</given-names></name><name><surname>Newcombe</surname><given-names>J</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Fratta</surname><given-names>P</given-names></name><name><surname>Raj</surname><given-names>T</given-names></name></person-group><article-title>Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions</article-title><source>Acta Neuropathol</source><year>2022</year><volume>143</volume><fpage>383</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">34961893</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Antion</surname><given-names>MD</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Spencer</surname><given-names>CM</given-names></name><name><surname>Paylor</surname><given-names>R</given-names></name><name><surname>Klann</surname><given-names>E</given-names></name></person-group><article-title>Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression</article-title><source>Neuron</source><year>2006</year><volume>51</volume><fpage>441</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">16908410</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>QH</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>chen</surname><given-names>Wang C</given-names></name></person-group><article-title>Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates</article-title><source>J Mol Biol</source><year>2006</year><volume>364</volume><fpage>323</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">17010992</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>N</given-names></name><name><surname>Korhonen</surname><given-names>S</given-names></name><name><surname>Hoffmann</surname><given-names>D</given-names></name><name><surname>Leskelä</surname><given-names>S</given-names></name><name><surname>Rostalski</surname><given-names>H</given-names></name><name><surname>Remes</surname><given-names>AM</given-names></name><name><surname>Honkakoski</surname><given-names>P</given-names></name><name><surname>Solje</surname><given-names>E</given-names></name><name><surname>Haapasalo</surname><given-names>A</given-names></name></person-group><article-title>Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration—Insights into disease mechanisms and current therapeutic approaches</article-title><source>Molecular Psychiatry</source><year>2021</year><volume>27</volume><issue>3</issue><fpage>1300</fpage><lpage>1309</lpage><comment>2021 27</comment><pub-id pub-id-type="pmcid">PMC9095474</pub-id><pub-id pub-id-type="pmid">34799692</pub-id><pub-id pub-id-type="doi">10.1038/s41380-021-01384-8</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouri</surname><given-names>N</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>Dombroski</surname><given-names>B</given-names></name><name><surname>Younkin</surname><given-names>CS</given-names></name><name><surname>Serie</surname><given-names>DJ</given-names></name><name><surname>Soto-Ortolaza</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Finch</surname><given-names>NCA</given-names></name><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Fujioka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><pub-id pub-id-type="pmcid">PMC4469997</pub-id><pub-id pub-id-type="pmid">26077951</pub-id><pub-id pub-id-type="doi">10.1038/ncomms8247</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>LI</given-names></name><name><surname>Herrera</surname><given-names>MG</given-names></name><name><surname>Winklhofer</surname><given-names>KF</given-names></name></person-group><article-title>The Role of Ubiquitin in Regulating Stress Granule Dynamics</article-title><source>Front Physiol</source><year>2022</year><volume>0</volume><elocation-id>1043</elocation-id><pub-id pub-id-type="pmcid">PMC9174786</pub-id><pub-id pub-id-type="pmid">35694405</pub-id><pub-id pub-id-type="doi">10.3389/fphys.2022.910759</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>LI</given-names></name><name><surname>Herrera</surname><given-names>MG</given-names></name><name><surname>Winklhofer</surname><given-names>KF</given-names></name></person-group><article-title>The Role of Ubiquitin in Regulating Stress Granule Dynamics</article-title><source>Front Physiol</source><year>2022</year><volume>13</volume><elocation-id>1043</elocation-id><pub-id pub-id-type="doi">10.3389/FPHYS.2022.910759/BIBTEX</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krichevsky</surname><given-names>AM</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name></person-group><article-title>Neuronal RNA granules: A link between RNA localization and stimulation-dependent translation</article-title><source>Neuron</source><year>2001</year><volume>32</volume><fpage>683</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">11719208</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langfelder</surname><given-names>P</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name></person-group><article-title>WGCNA: An R package for weighted correlation network analysis</article-title><source>BMC Bioinformatics</source><year>2008</year><pub-id pub-id-type="pmcid">PMC2631488</pub-id><pub-id pub-id-type="pmid">19114008</pub-id><pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langfelder</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Oldham</surname><given-names>MC</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name></person-group><article-title>Is My Network Module Preserved and Reproducible?</article-title><source>PLoS Comput Biol</source><year>2011</year><volume>7</volume><elocation-id>1001057</elocation-id><pub-id pub-id-type="pmcid">PMC3024255</pub-id><pub-id pub-id-type="pmid">21283776</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1001057</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Rohrer</surname><given-names>JD</given-names></name><name><surname>Bandopadhyay</surname><given-names>R</given-names></name><name><surname>Fry</surname><given-names>C</given-names></name><name><surname>Ahmed</surname><given-names>Z</given-names></name><name><surname>Isaacs</surname><given-names>AM</given-names></name><name><surname>Brelstaff</surname><given-names>JH</given-names></name><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Warren</surname><given-names>JD</given-names></name><name><surname>Troakes</surname><given-names>C</given-names></name><name><surname>King</surname><given-names>A</given-names></name><etal/></person-group><article-title>A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>2548</fpage><lpage>2564</lpage><pub-id pub-id-type="pmcid">PMC3170529</pub-id><pub-id pub-id-type="pmid">21752791</pub-id><pub-id pub-id-type="doi">10.1093/brain/awr160</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Rohrer</surname><given-names>JD</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name></person-group><article-title>Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations</article-title><source>Neuropathol Appl Neurobiol</source><year>2015</year><volume>41</volume><fpage>858</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">26041104</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leek</surname><given-names>JT</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Parker</surname><given-names>HS</given-names></name><name><surname>Jaffe</surname><given-names>AE</given-names></name><name><surname>Storey</surname><given-names>JD</given-names></name></person-group><article-title>The SVA package for removing batch effects and other unwanted variation in high-throughput experiments</article-title><source>Bioinformatics</source><year>2012</year><pub-id pub-id-type="pmcid">PMC3307112</pub-id><pub-id pub-id-type="pmid">22257669</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bts034</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Ao</surname><given-names>N</given-names></name><name><surname>Ayres</surname><given-names>M</given-names></name><name><surname>Bensinger</surname><given-names>A</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Boe</surname><given-names>AF</given-names></name><name><surname>Boguski</surname><given-names>MS</given-names></name><name><surname>Brockway</surname><given-names>KS</given-names></name><name><surname>Byrnes</surname><given-names>EJ</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Genome-wide atlas of gene expression in the adult mouse brain</article-title><source>Nature</source><year>2006</year><volume>445</volume><issue>7124</issue><fpage>168</fpage><lpage>176</lpage><comment>2006 445</comment><pub-id pub-id-type="pmid">17151600</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Oyang</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Yi</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The functions and mechanisms of prefoldin complex and prefoldin-subunits</article-title><source>Cell Biosci</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmcid">PMC7370476</pub-id><pub-id pub-id-type="pmid">32699605</pub-id><pub-id pub-id-type="doi">10.1186/s13578-020-00446-8</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>S-C</given-names></name></person-group><article-title>Synaptic Paths to Neurodegeneration: The Emerging Role of TDP-43 and FUS in Synaptic Functions</article-title><year>2018</year><pub-id pub-id-type="pmcid">PMC5925147</pub-id><pub-id pub-id-type="pmid">29755516</pub-id><pub-id pub-id-type="doi">10.1155/2018/8413496</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>KC</given-names></name><name><surname>Mills</surname><given-names>IP</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name></person-group><article-title>Interactions between Hsp7O and the hydrophobic core of alpha-synuclein inhibit fibril assembly</article-title><source>Biochemistry</source><year>2008</year><volume>47</volume><fpage>12614</fpage><lpage>12625</lpage><pub-id pub-id-type="pmcid">PMC2648307</pub-id><pub-id pub-id-type="pmid">18975920</pub-id><pub-id pub-id-type="doi">10.1021/bi801475r</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lum</surname><given-names>LS</given-names></name><name><surname>Sultzman</surname><given-names>LA</given-names></name><name><surname>Kaufman</surname><given-names>RJ</given-names></name><name><surname>Linzer</surname><given-names>DI</given-names></name><name><surname>Wu</surname><given-names>BJ</given-names></name></person-group><article-title>A cloned human CCAAT-box-binding factor stimulates transcription from the human hsp7O promoter</article-title><source>Mol Cell Biol</source><year>1990</year><volume>10</volume><fpage>6709</fpage><lpage>6717</lpage><pub-id pub-id-type="pmcid">PMC362949</pub-id><pub-id pub-id-type="pmid">2247079</pub-id><pub-id pub-id-type="doi">10.1128/mcb.10.12.6709</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margolin</surname><given-names>DH</given-names></name><name><surname>Kousi</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>Y-M</given-names></name><name><surname>Lim</surname><given-names>ET</given-names></name><name><surname>Schmahmann</surname><given-names>JD</given-names></name><name><surname>Hall</surname><given-names>JE</given-names></name><name><surname>Adam</surname><given-names>I</given-names></name><name><surname>Dwyer</surname><given-names>A</given-names></name><name><surname>Plummer</surname><given-names>L</given-names></name><name><surname>Aldrin</surname><given-names>Sv</given-names></name><name><surname>O’rourke</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ataxia, Dementia, and Hypogonadotropism Caused by Disordered Ubiquitination</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>1992</fpage><lpage>2003</lpage><pub-id pub-id-type="pmcid">PMC3738065</pub-id><pub-id pub-id-type="pmid">23656588</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1215993</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateju</surname><given-names>D</given-names></name><name><surname>Franzmann</surname><given-names>TM</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Kopach</surname><given-names>A</given-names></name><name><surname>Boczek</surname><given-names>EE</given-names></name><name><surname>Maharana</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>HO</given-names></name><name><surname>Carra</surname><given-names>S</given-names></name><name><surname>Hyman</surname><given-names>AA</given-names></name><name><surname>Alberti</surname><given-names>S</given-names></name></person-group><article-title>An aberrant phase transition of stress granules triggered by misfolded protein and prevented by chaperone function</article-title><source>EMBO J</source><year>2017</year><volume>36</volume><fpage>1669</fpage><lpage>1687</lpage><pub-id pub-id-type="pmcid">PMC5470046</pub-id><pub-id pub-id-type="pmid">28377462</pub-id><pub-id pub-id-type="doi">10.15252/embj.201695957</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathys</surname><given-names>H</given-names></name><name><surname>Davila-Velderrain</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Mohammadi</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>JZ</given-names></name><name><surname>Menon</surname><given-names>M</given-names></name><name><surname>liang</surname><given-names>He</given-names></name><name><surname>Abdurrob</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Martorell</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Single-cell transcriptomic analysis of Alzheimer’s disease</article-title><source>Nature</source><pub-id pub-id-type="doi">10.1038/s41586-019-1195-2</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMillan</surname><given-names>CT</given-names></name><name><surname>Russ</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>EM</given-names></name><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>McCluskey</surname><given-names>L</given-names></name><name><surname>Elman</surname><given-names>L</given-names></name><name><surname>van Deerlin</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name></person-group><article-title>C9orf72 promoter hypermethylation is neuroprotective</article-title><source>Neurology</source><year>2015</year><volume>84</volume><fpage>1622</fpage><lpage>1630</lpage><pub-id pub-id-type="pmcid">PMC4409587</pub-id><pub-id pub-id-type="pmid">25795648</pub-id><pub-id pub-id-type="doi">10.1212/WNL.0000000000001495</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meadows</surname><given-names>JP</given-names></name><name><surname>Guzman-Karlsson</surname><given-names>MC</given-names></name><name><surname>Phillips</surname><given-names>S</given-names></name><name><surname>Holleman</surname><given-names>C</given-names></name><name><surname>Posey</surname><given-names>JL</given-names></name><name><surname>Day</surname><given-names>JJ</given-names></name><name><surname>Hablitz</surname><given-names>JJ</given-names></name><name><surname>Sweatt</surname><given-names>JD</given-names></name></person-group><article-title>DNA methylation regulates neuronal glutamatergic synaptic scaling</article-title><source>Sci Signal</source><year>2015</year><volume>8</volume><fpage>ra6l</fpage><pub-id pub-id-type="pmcid">PMC4764068</pub-id><pub-id pub-id-type="pmid">26106219</pub-id><pub-id pub-id-type="doi">10.1126/scisignal.aab0715</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menden</surname><given-names>K</given-names></name><name><surname>Francescatto</surname><given-names>M</given-names></name><name><surname>Nyima</surname><given-names>T</given-names></name><name><surname>Blauwendraat</surname><given-names>C</given-names></name><name><surname>Dhingra</surname><given-names>A</given-names></name><name><surname>Castillo-Lizardo</surname><given-names>M</given-names></name><name><surname>Fernandes</surname><given-names>N</given-names></name><name><surname>Kaurani</surname><given-names>L</given-names></name><name><surname>Kronenberg-Versteeg</surname><given-names>D</given-names></name><name><surname>Atasu</surname><given-names>B</given-names></name><name><surname>Sadikoglou</surname><given-names>E</given-names></name><etal/></person-group><article-title>A multi-omics dataset for the analysis of Frontotemporal Dementia genetic subtypes</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2020.12.01.405894</elocation-id><pub-id pub-id-type="doi">10.1101/2020.12.01.405894</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mevissen</surname><given-names>TET</given-names></name><name><surname>Hospenthal</surname><given-names>MK</given-names></name><name><surname>Geurink</surname><given-names>PP</given-names></name><name><surname>Elliott</surname><given-names>PR</given-names></name><name><surname>Akutsu</surname><given-names>M</given-names></name><name><surname>Arnaudo</surname><given-names>N</given-names></name><name><surname>Ekkebus</surname><given-names>R</given-names></name><name><surname>Kulathu</surname><given-names>Y</given-names></name><name><surname>Wauer</surname><given-names>T</given-names></name><name><surname>el Oualid</surname><given-names>F</given-names></name><name><surname>Freund</surname><given-names>SMV</given-names></name><etal/></person-group><article-title>OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis</article-title><source>Cell</source><year>2013</year><volume>154</volume><fpage>169</fpage><pub-id pub-id-type="pmcid">PMC3705208</pub-id><pub-id pub-id-type="pmid">23827681</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2013.05.046</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>S</given-names></name></person-group><article-title>Managing stress granule disassembly with ubiquitin and its cousin</article-title><source>Signal Transduction and Targeted Therapy</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>2</lpage><comment>2021 6</comment><pub-id pub-id-type="pmcid">PMC8586141</pub-id><pub-id pub-id-type="pmid">34764249</pub-id><pub-id pub-id-type="doi">10.1038/s41392-021-00782-2</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murley</surname><given-names>AG</given-names></name><name><surname>Rowe</surname><given-names>JB</given-names></name></person-group><article-title>Neurotransmitter deficits from frontotemporal lobar degeneration</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>1263</fpage><lpage>1285</lpage><pub-id pub-id-type="pmcid">PMC5917782</pub-id><pub-id pub-id-type="pmid">29373632</pub-id><pub-id pub-id-type="doi">10.1093/brain/awx327</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalavadi</surname><given-names>VC</given-names></name><name><surname>Muddashetty</surname><given-names>RS</given-names></name><name><surname>Gross</surname><given-names>C</given-names></name><name><surname>Bassell</surname><given-names>GJ</given-names></name></person-group><article-title>Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>2582</fpage><lpage>2587</lpage><pub-id pub-id-type="pmcid">PMC3427762</pub-id><pub-id pub-id-type="pmid">22357842</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5057-11.2012</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Sampathu</surname><given-names>DM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Truax</surname><given-names>AC</given-names></name><name><surname>Micsenyi</surname><given-names>MC</given-names></name><name><surname>Chou</surname><given-names>TT</given-names></name><name><surname>Bruce</surname><given-names>J</given-names></name><name><surname>Schuck</surname><given-names>T</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>McCluskey</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>130</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">17023659</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>AA</given-names></name><name><surname>Bell</surname><given-names>JT</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name><name><surname>Pritchard</surname><given-names>JK</given-names></name><name><surname>Gilad</surname><given-names>Y</given-names></name></person-group><article-title>A Genome-Wide Study of DNA Methylation Patterns and Gene Expression Levels in Multiple Human and Chimpanzee Tissues</article-title><source>PLoS Genet</source><year>2011</year><volume>7</volume><elocation-id>1001316</elocation-id><pub-id pub-id-type="pmcid">PMC3044686</pub-id><pub-id pub-id-type="pmid">21383968</pub-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1001316</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Pasquale</surname><given-names>R</given-names></name><name><surname>Pignatelli</surname><given-names>M</given-names></name><name><surname>Parsons</surname><given-names>MP</given-names></name><name><surname>Jeans</surname><given-names>AF</given-names></name><name><surname>Taylor</surname><given-names>HBC</given-names></name></person-group><article-title>Friend or Foe? The Varied Faces of Homeostatic Synaptic Plasticity in Neurodegenerative Disease</article-title><year>2021</year><pub-id pub-id-type="pmcid">PMC8702499</pub-id><pub-id pub-id-type="pmid">34955753</pub-id><pub-id pub-id-type="doi">10.3389/fncel.2021.782768</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrola</surname><given-names>L</given-names></name><name><surname>Espert</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Claramunt</surname><given-names>R</given-names></name><name><surname>Shy</surname><given-names>ME</given-names></name><name><surname>Palau</surname><given-names>F</given-names></name></person-group><article-title>GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria</article-title><pub-id pub-id-type="pmid">15772096</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pemberton</surname><given-names>S</given-names></name><name><surname>Madiona</surname><given-names>K</given-names></name><name><surname>Pieri</surname><given-names>L</given-names></name><name><surname>Kabani</surname><given-names>M</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name></person-group><article-title>Hsc7O protein interaction with soluble and fibrillar alpha-synuclein</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>34690</fpage><lpage>34699</lpage><pub-id pub-id-type="pmcid">PMC3186418</pub-id><pub-id pub-id-type="pmid">21832061</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M111.261321</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pottier</surname><given-names>C</given-names></name><name><surname>Mateiu</surname><given-names>L</given-names></name><name><surname>Baker</surname><given-names>MC</given-names></name><name><surname>Dejesus-Hernandez</surname><given-names>M</given-names></name><name><surname>Teixeira Vicente</surname><given-names>C</given-names></name><name><surname>Finch</surname><given-names>NA</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>van Blitterswijk</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations</article-title><source>Brain</source><year>2022</year><volume>145</volume><fpage>2472</fpage><lpage>2485</lpage><pub-id pub-id-type="pmcid">PMC9337811</pub-id><pub-id pub-id-type="pmid">34918030</pub-id><pub-id pub-id-type="doi">10.1093/brain/awab437</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>e47</fpage><pub-id pub-id-type="pmcid">PMC4402510</pub-id><pub-id pub-id-type="pmid">25605792</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouillard</surname><given-names>AD</given-names></name><name><surname>Gundersen</surname><given-names>GW</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Monteiro</surname><given-names>CD</given-names></name><name><surname>McDermott</surname><given-names>MG</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><article-title>The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins</article-title><source>Database</source><year>2016</year><comment>2016</comment><pub-id pub-id-type="pmcid">PMC4930834</pub-id><pub-id pub-id-type="pmid">27374120</pub-id><pub-id pub-id-type="doi">10.1093/database/baw100</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Contreras</surname><given-names>MY</given-names></name><name><surname>Kouri</surname><given-names>N</given-names></name><name><surname>Cook</surname><given-names>CN</given-names></name><name><surname>Serie</surname><given-names>DJ</given-names></name><name><surname>Heckman</surname><given-names>MG</given-names></name><name><surname>Finch</surname><given-names>NA</given-names></name><name><surname>Caselli</surname><given-names>RJ</given-names></name><name><surname>Uitti</surname><given-names>RJ</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Graff-Radford</surname><given-names>N</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci</article-title><source>Mol Neurodegener</source><year>2018</year><volume>13</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmcid">PMC6038352</pub-id><pub-id pub-id-type="pmid">29986742</pub-id><pub-id pub-id-type="doi">10.1186/s13024-018-0267-3</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Schalkwyk</surname><given-names>LC</given-names></name><name><surname>Pidsley</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>CCY</given-names></name></person-group><article-title>wateRmelon: Illumina 450 methylation array normalization and metrics</article-title><source>R package version 1.2.2</source><year>2013</year></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>MF</given-names></name><name><surname>Gan</surname><given-names>ZY</given-names></name><name><surname>Komander</surname><given-names>D</given-names></name><name><surname>Dewson</surname><given-names>G</given-names></name></person-group><article-title>Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities</article-title><source>Cell Death &amp; Differentiation</source><year>2021</year><volume>28</volume><issue>2</issue><fpage>570</fpage><lpage>590</lpage><comment>2021 28</comment><pub-id pub-id-type="pmcid">PMC7862249</pub-id><pub-id pub-id-type="pmid">33414510</pub-id><pub-id pub-id-type="doi">10.1038/s41418-020-00706-7</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schofield</surname><given-names>E</given-names></name><name><surname>Kersaitis</surname><given-names>C</given-names></name><name><surname>Shepherd</surname><given-names>CE</given-names></name><name><surname>Kril</surname><given-names>JJ</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name></person-group><article-title>Severity of gliosis in Pick’s disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>827</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">12615642</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sephton</surname><given-names>CF</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><article-title>The function of RNA-binding proteins at the synapse: implications for neurodegeneration</article-title><source>Cellular and Molecular Life Sciences</source><year>2015</year><volume>72</volume><fpage>3621</fpage><pub-id pub-id-type="pmcid">PMC4565867</pub-id><pub-id pub-id-type="pmid">26047658</pub-id><pub-id pub-id-type="doi">10.1007/s00018-015-1943-x</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethna</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Robison</surname><given-names>AJ</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Enhanced expression of ADCY1 underlies aberrant neuronal signalling and behaviour in a syndromic autism model</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><pub-id pub-id-type="pmcid">PMC5321753</pub-id><pub-id pub-id-type="pmid">28218269</pub-id><pub-id pub-id-type="doi">10.1038/ncomms14359</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shireby</surname><given-names>G</given-names></name><name><surname>Dempster</surname><given-names>EL</given-names></name><name><surname>Policicchio</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>RG</given-names></name><name><surname>Pishva</surname><given-names>E</given-names></name><name><surname>Chioza</surname><given-names>B</given-names></name><name><surname>Davies</surname><given-names>JP</given-names></name><name><surname>Burrage</surname><given-names>J</given-names></name><name><surname>Lunnon</surname><given-names>K</given-names></name><name><surname>Seiler Vellame</surname><given-names>D</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><etal/></person-group><article-title>DNA methylation signatures of Alzheimer’s disease neuropathology in the cortex are primarily driven by variation in non-neuronal celltypes</article-title><source>Nature Communications</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><comment>2022 13</comment><pub-id pub-id-type="pmcid">PMC9509387</pub-id><pub-id pub-id-type="pmid">36153390</pub-id><pub-id pub-id-type="doi">10.1038/s41467-022-33394-7</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skene</surname><given-names>NG</given-names></name><name><surname>Grant</surname><given-names>SGN</given-names></name></person-group><article-title>Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment</article-title><source>Front Neurosci</source><year>2016</year><volume>10</volume><fpage>16</fpage><pub-id pub-id-type="pmcid">PMC4730103</pub-id><pub-id pub-id-type="pmid">26858593</pub-id><pub-id pub-id-type="doi">10.3389/fnins.2016.00016</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RG</given-names></name><name><surname>Pishva</surname><given-names>E</given-names></name><name><surname>Shireby</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>AR</given-names></name><name><surname>Roubroeks</surname><given-names>JAY</given-names></name><name><surname>Hannon</surname><given-names>E</given-names></name><name><surname>Wheildon</surname><given-names>G</given-names></name><name><surname>Mastroeni</surname><given-names>D</given-names></name><name><surname>Gasparoni</surname><given-names>G</given-names></name><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Giese</surname><given-names>A</given-names></name><etal/></person-group><article-title>A meta-analysis of epigenome-wide association studies in Alzheimer’s disease highlights novel differentially methylated loci across cortex</article-title><source>Nature Communications</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><comment>2021 12</comment><pub-id pub-id-type="pmcid">PMC8192929</pub-id><pub-id pub-id-type="pmid">34112773</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-23243-4</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sörgjerd</surname><given-names>KM</given-names></name><name><surname>Zako</surname><given-names>T</given-names></name><name><surname>Sakono</surname><given-names>M</given-names></name><name><surname>Stirling</surname><given-names>PC</given-names></name><name><surname>Leroux</surname><given-names>MR</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Sekimoto</surname><given-names>M</given-names></name><name><surname>Saido</surname><given-names>TC</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name></person-group><article-title>Human prefoldin inhibits amyloid-ß (Aß) fibrillation and contributes to formation of nontoxic Aß aggregates</article-title><source>Biochemistry</source><year>2013</year><volume>52</volume><fpage>3532</fpage><lpage>3542</lpage><pub-id pub-id-type="pmid">23614719</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Morris</surname><given-names>TJ</given-names></name><name><surname>Webster</surname><given-names>AP</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Beck</surname><given-names>S</given-names></name><name><surname>Feber</surname><given-names>A</given-names></name><name><surname>Teschendorff</surname><given-names>AE</given-names></name></person-group><article-title>ChAMP: Updated methylation analysis pipeline for Illumina BeadChips</article-title><source>Bioinformatics</source><year>2017</year><pub-id pub-id-type="pmcid">PMC5860089</pub-id><pub-id pub-id-type="pmid">28961746</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btx513</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolay</surname><given-names>N</given-names></name><name><surname>Buchberger</surname><given-names>A</given-names></name></person-group><article-title>Role of the Ubiquitin System in Stress Granule Metabolism</article-title><source>International Journal of Molecular Sciences</source><year>2022</year><volume>23</volume><elocation-id>3624</elocation-id><comment>2022, Vol 23, Page 3624</comment><pub-id pub-id-type="pmcid">PMC8999021</pub-id><pub-id pub-id-type="pmid">35408984</pub-id><pub-id pub-id-type="doi">10.3390/ijms23073624</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toomey</surname><given-names>CE</given-names></name><name><surname>Heywood</surname><given-names>W</given-names></name><name><surname>Benson</surname><given-names>BC</given-names></name><name><surname>Packham</surname><given-names>G</given-names></name><name><surname>Mills</surname><given-names>K</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name></person-group><article-title>Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer’s disease</article-title><source>Brain Pathol</source><year>2020</year><volume>30</volume><fpage>794</fpage><lpage>810</lpage><pub-id pub-id-type="pmcid">PMC8018003</pub-id><pub-id pub-id-type="pmid">32267026</pub-id><pub-id pub-id-type="doi">10.1111/bpa.12842</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderkraats</surname><given-names>ND</given-names></name><name><surname>Hiken</surname><given-names>JF</given-names></name><name><surname>Decker</surname><given-names>KF</given-names></name><name><surname>Edwards</surname><given-names>JR</given-names></name></person-group><article-title>Discovering high-resolution patterns of differential DNA methylation that correlate with gene expression changes</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><fpage>6816</fpage><lpage>6827</lpage><pub-id pub-id-type="pmcid">PMC3737560</pub-id><pub-id pub-id-type="pmid">23748561</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkt482</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vihma</surname><given-names>H</given-names></name><name><surname>Luhakooder</surname><given-names>M</given-names></name><name><surname>Pruunsild</surname><given-names>P</given-names></name><name><surname>Timmusk</surname><given-names>T</given-names></name></person-group><article-title>Regulation of different human NFAT isoforms by neuronal activity</article-title><source>J Neurochem</source><year>2016</year><volume>137</volume><fpage>394</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">26851544</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>ìş</surname><given-names>Ö</given-names></name><name><surname>Reddy</surname><given-names>JS</given-names></name><name><surname>Tutor-New</surname><given-names>FQ</given-names></name><name><surname>Casey</surname><given-names>MC</given-names></name><name><surname>Carrasquillo</surname><given-names>MM</given-names></name><name><surname>Oatman</surname><given-names>SR</given-names></name><name><surname>Min</surname><given-names>Y</given-names></name><name><surname>Asmann</surname><given-names>YW</given-names></name><name><surname>Funk</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alzheimer’s disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions</article-title><source>J Clin Invest</source><year>2022</year><fpage>132</fpage><pub-id pub-id-type="pmcid">PMC8759790</pub-id><pub-id pub-id-type="pmid">34813500</pub-id><pub-id pub-id-type="doi">10.1172/JCI149904</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Reddy</surname><given-names>JS</given-names></name><name><surname>Carrasquillo</surname><given-names>MM</given-names></name><name><surname>Asmann</surname><given-names>YW</given-names></name><name><surname>Funk</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Malphrus</surname><given-names>KG</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Price</surname><given-names>ND</given-names></name><etal/></person-group><article-title>Conserved Architecture of Brain Transcriptome Changes between Alzheimer’s Disease and Progressive Supranuclear Palsy in Pathologically Affected and Unaffected Regions</article-title><source>bioRxiv</source><year>2021</year><elocation-id>2021.01.18.426999</elocation-id><pub-id pub-id-type="doi">10.1101/2021.01.18.426999</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Schwarz</surname><given-names>SC</given-names></name><name><surname>Tost</surname><given-names>J</given-names></name><name><surname>Trümbach</surname><given-names>D</given-names></name><name><surname>Winter</surname><given-names>P</given-names></name><name><surname>Busato</surname><given-names>F</given-names></name><name><surname>Tacik</surname><given-names>P</given-names></name><name><surname>Windhorst</surname><given-names>AC</given-names></name><name><surname>Fagny</surname><given-names>M</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>McLean</surname><given-names>C</given-names></name><etal/></person-group><article-title>Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1</article-title><source>Nat Commun</source><year>2018</year><pub-id pub-id-type="pmcid">PMC6062504</pub-id><pub-id pub-id-type="pmid">30050033</pub-id><pub-id pub-id-type="doi">10.1038/s41467-018-05325-y</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Strand</surname><given-names>C</given-names></name><name><surname>Pittman</surname><given-names>A</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name></person-group><article-title>Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>1566</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">17525140</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>The Innovation</source><year>2021</year><volume>2</volume><elocation-id>100141</elocation-id><pub-id pub-id-type="pmcid">PMC8454663</pub-id><pub-id pub-id-type="pmid">34557778</pub-id><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Bruni</surname><given-names>AC</given-names></name><name><surname>Maletta</surname><given-names>RG</given-names></name><name><surname>Colao</surname><given-names>R</given-names></name><name><surname>Fratta</surname><given-names>P</given-names></name><name><surname>Polke</surname><given-names>JM</given-names></name><name><surname>Sweeney</surname><given-names>MG</given-names></name><name><surname>Mudanohwo</surname><given-names>E</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><etal/></person-group><article-title>The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients</article-title><source>Acta Neuropathol</source><year>2015</year><volume>129</volume><fpage>715</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">25716178</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>JS</given-names></name><name><surname>Karch</surname><given-names>CM</given-names></name><name><surname>Fan</surname><given-names>CC</given-names></name><name><surname>Bonham</surname><given-names>LW</given-names></name><name><surname>Kouri</surname><given-names>N</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Höglinger</surname><given-names>GU</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name><etal/></person-group><article-title>Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia</article-title><source>Acta Neuropathol</source><year>2017</year><volume>133</volume><fpage>825</fpage><pub-id pub-id-type="pmcid">PMC5429027</pub-id><pub-id pub-id-type="pmid">28271184</pub-id><pub-id pub-id-type="doi">10.1007/s00401-017-1693-y</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisel</surname><given-names>A</given-names></name><name><surname>Muñoz-Manchado</surname><given-names>AB</given-names></name><name><surname>Codeluppi</surname><given-names>S</given-names></name><name><surname>Lönnerberg</surname><given-names>P</given-names></name><name><surname>La Manno</surname><given-names>G</given-names></name><name><surname>Juréus</surname><given-names>A</given-names></name><name><surname>Marques</surname><given-names>S</given-names></name><name><surname>Munguba</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name><name><surname>Rolny</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq</article-title><source>Science (1979)</source><year>2015</year><volume>347</volume><fpage>1138</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">25700174</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Silva</surname><given-names>TC</given-names></name><name><surname>Young</surname><given-names>JI</given-names></name><name><surname>Gomez</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>MA</given-names></name><name><surname>Hamilton-Nelson</surname><given-names>KL</given-names></name><name><surname>Kunkle</surname><given-names>BW</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer’s disease</article-title><source>Nature Communications</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><comment>2020 11</comment><pub-id pub-id-type="pmcid">PMC7704686</pub-id><pub-id pub-id-type="pmid">33257653</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-19791-w</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Majid</surname><given-names>MC</given-names></name><name><surname>Soil</surname><given-names>JM</given-names></name><name><surname>Brickner</surname><given-names>JR</given-names></name><name><surname>Dango</surname><given-names>S</given-names></name><name><surname>Mosammaparast</surname><given-names>N</given-names></name></person-group><article-title>Noncanonical regulation of alkylation damage resistance by the OTUD4 deubiquitinase</article-title><source>EMBO J</source><year>2015</year><volume>34</volume><fpage>1687</fpage><lpage>1703</lpage><pub-id pub-id-type="pmcid">PMC4475402</pub-id><pub-id pub-id-type="pmid">25944111</pub-id><pub-id pub-id-type="doi">10.15252/embj.201490497</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Mudge</surname><given-names>MC</given-names></name><name><surname>Soil</surname><given-names>JM</given-names></name><name><surname>Rodrigues</surname><given-names>RB</given-names></name><name><surname>Byrum</surname><given-names>AK</given-names></name><name><surname>Schwarzkopf</surname><given-names>EA</given-names></name><name><surname>Bradstreet</surname><given-names>TR</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Edelson</surname><given-names>BT</given-names></name><name><surname>Mosammaparast</surname><given-names>N</given-names></name></person-group><article-title>OTUD4 Is a Phospho-Activated K63 Deubiquitinase that Regulates MyD88-Dependent Signaling</article-title><source>Mol Cell</source><year>2018</year><volume>69</volume><fpage>505</fpage><lpage>516</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmcid">PMC6819006</pub-id><pub-id pub-id-type="pmid">29395066</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2018.01.009</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Danbolt</surname><given-names>NC</given-names></name></person-group><article-title>Glutamate as a neurotransmitter in the healthy brain</article-title><source>J Neural Transm</source><year>2014</year><volume>121</volume><fpage>799</fpage><pub-id pub-id-type="pmcid">PMC4133642</pub-id><pub-id pub-id-type="pmid">24578174</pub-id><pub-id pub-id-type="doi">10.1007/s00702-014-1180-8</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Outline of the study design and analysis framework.</title><p>FTLD – Frontotemporal lobar degeneration; PSP – Progressive supranuclear palsy. Figure created with BioRender.</p></caption><graphic xlink:href="EMS156182-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Brain cell-type proportion estimates derived from bulk DNA methylation data in frontal lobe of frontotemporal lobar degeneration (FTLD) and controls.</title><p>*indicates significant differences for each cell-type between FTLD subtypes and the corresponding controls; pairwise comparisons were performed using the Wilcoxon rank sum test, and adjusted p-values &lt;0.05 we considered significant. CTRL – controls; TDPA_GRN – FTLD with TDP-43 positive inclusions (FTLD-TDP) subtype A, carriers of <italic>GRN</italic> mutations; TDPA_C9 – FTLD-TDP subtype A, carriers of <italic>C9orf72</italic> repeat expansion; TDPB_C9 – FTLD-TDP subtype B, carriers of <italic>C9orf72</italic> repeat expansion; TDPC – FTLD-TDP subtype C, sporadic; MAPT – FTLD with tau positive inclusions (FTLD-Tau), carriers of <italic>MAPT</italic> mutations; PSP – FTLD-Tau, sporadic progressive supranuclear palsy (PSP); Neurons – NeuN+; Oligodendrocytes – SOX10+; other glial cells – NeuN-/SOX1O-.</p></caption><graphic xlink:href="EMS156182-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Differentially methylated positions identified in a case-control FTLD cross-cohort meta-analysis.</title><p><bold>a)</bold> Manhattan plot showing associations between single DNA methylation sites (CpGs) and FTLD from the meta-analysis random-effect results (total N = 234). CpGs are plotted on the x-axis according to their positions on each chromosome against association with FTLD on the y-axis (− log 10 p-value). The top red line indicates the conservative Bonferroni significance threshold (α) of p = 1.37 × 10<sup>−7</sup>. Green points indicate CpGs passing the Bonferroni threshold. The blue line indicates a less stringent threshold of p = 2.70 × 10<sup>−6</sup> (FDR p = 0.10). <bold>b)</bold> Forest plot depicting the CpG in <italic>OTUD4,</italic> which is significantly hypomethylated in FTLD compared to controls in the cross-cohort meta-analysis (FTLD1 N=23, FTLD2 N=48, and FTLD3 N=163). <bold>c)</bold> Forest plot depicting the CpG in <italic>NFATC1,</italic> which is significantly hypermethylated in FTLD compared to controls in the cross-cohort metaanalysis (FTLD1 N=23, FTLD2 N=48, and FTLD3 N=163).</p></caption><graphic xlink:href="EMS156182-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Boxplots showing gene expression levels for the two EWAS meta-analysis hits in FTLD-TDP and controls.</title><p>RNA sequencing data from Hasan et al. [<xref ref-type="bibr" rid="R30">30</xref>] adjusted for age, sex, and RNA integrity number was used. Log2-transformed gene expression data is shown in the y-axis, and non-paired t-test p-value for the comparison between FTLD-TDP (N= 80) and controls (N= 48) is denoted at the top.</p></caption><graphic xlink:href="EMS156182-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Bar plots of protein quantifications for the EWAS meta-analysis hit <italic>OTUD4</italic> in FTLD-TDP subtypes and controls.</title><p>Out of the two EWAS meta-analysis hits, only the OTUD4 protein were detected in the proteomics data and are presented here. OTUD4 was detected in both fractions (pellet and supernatant). Two pooled samples (2 × 3 samples) per group were analysed. The average values were obtained for each group, and fold-changes were calculated comparing FTLD-TDP subtypes with controls. Bar plots show mean fold-change.</p></caption><graphic xlink:href="EMS156182-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Immunoreactivity of OTUD4 in FTLD-TDP (N=4 type A and N=3 type C) and controls (N=3).</title><p>Immunohistochemical analysis was carried out in FFPE frontal cortex tissue from FTLD-TDP cases and controls overlapping with FTLD1, using a rabbit anti-OTUD4 antibody (Atlas Antibodies HPA036623, 1:200). Scale-bars represent 100 μm.</p></caption><graphic xlink:href="EMS156182-f006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title>Module-trait correlations for the FTLD co-methylation networks.</title><p><bold>a)</bold> FTLD1; <bold>b)</bold> FTLD3; <bold>c)</bold> FTLD2. The rows represent the co-methylation module eigengenes (ME) and their colours, and the column represents the correlation of the methylation levels of CpGs in each module with the disease status. P-values are presented within each cell and the colour scale at the right indicates the strength of the correlation (darker cells depict stronger correlations, with blue representing negative and red representing positive correlations).</p></caption><graphic xlink:href="EMS156182-f007"/></fig><fig id="F8" position="float"><label>Figure 8</label><caption><title>Functional enrichment for the FTLD-associated co-methylation modules across the three networks.</title><p>Y-axis shows top enriched gene ontology terms, while x-axis depicts FTLD-associated modules in FTLD1 (green), FTLD2 (yellow) and FTLD3 (blue) co-methylation networks. Modules not showing enrichment for shared terms across the networks are not shown.</p></caption><graphic xlink:href="EMS156182-f008"/></fig><fig id="F9" position="float"><label>Figure 9</label><caption><title>Cell-type enrichment for all FTLD-associated co-methylation modules across the three co-methylation networks.</title><p>Green denotes FTLD-associated modules in the FTLD1 network; Yellow denotes FTLD-associated modules in the FTLD2 network; Blue denotes FTLD-associated modules in the FTLD3 network. Dark filled circles highlight the cell types found to be significantly enriched with adjusted p &lt; 0.05 after Bonferroni correction over all cell types within each module; the size of the circles represents the number of standard deviations (SD) from the mean. Cell-type enrichment analysis on the FTLD-related modules was performed using the package EWCE [<xref ref-type="bibr" rid="R73">73</xref>] and associated single-cell transcriptomic data [<xref ref-type="bibr" rid="R88">88</xref>].</p></caption><graphic xlink:href="EMS156182-f009"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Clinical and pathological characteristics of the three FTLD cohorts and selected models for cohort-specific EWAS.</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top">Cohort</th><th align="left" valign="top">Pathological FTLD subtypes present</th><th align="left" valign="top">Samples included after quality control + age/sex distribution</th><th align="left" valign="top">Regression models used for cohort-specific EWAS</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>FTLD1</bold></td><td align="left" valign="top">FTLD-TDP type A (<italic>C9oŗf72</italic> mutation carriers), and FTLD-TDP type C (sporadic)</td><td align="left" valign="top"><bold>15 FTLD donors:</bold> mean age±SD = 70.07±5.59 years, sex = 7M/8F<break/>
<list list-type="simple" id="L1"><list-item><label>-</label><p>7 FTLD-TDP <italic>C9oŗf72:</italic> mean age ±SD =66.86±4.85, sex = 3M/4F</p></list-item><list-item><label>-</label><p>8 FTLD-TDP sporadic: mean age ±SD =72.88±4.79, sex = 4M/4F</p></list-item></list>
<break/><bold>8 control donors:</bold> mean age±SD = 75.75±5.63 years, sex = 3M/5F</td><td align="left" valign="top"><italic>˜0 + disease + age + sex + SOX10<sup>+</sup> proportions + Double proportions + array</italic> (0 surrogate variables detected)</td></tr><tr><td align="left" valign="top"><bold>FTLD2[<xref ref-type="bibr" rid="R53">53</xref>]</bold></td><td align="left" valign="top">FTLD-TDP types A (<italic>GRN</italic> mutation carriers) and B (<italic>C9oŗf72</italic> mutation carriers), and FTLD-tau (FTDP-17 - <italic>MAPT</italic> mutation carriers)</td><td align="left" valign="top"><bold>34 FTLD donors:</bold> mean age±SD = 63.18±7.92 years, sex = 14M/20F
<break/>
<list list-type="simple" id="L2"><list-item><label>-</label><p>14 FTLD-TDP <italic>C9oŗf72:</italic> mean age±SD = 64.57±8.41, sex = 5M/9F</p></list-item><list-item><label>-</label><p>7 FTLD-TDP <italic>GRN:</italic> age±SD =65.57±7.63, sex = 2M/5F</p></list-item><list-item><label>-</label><p>13 FTLD-tau <italic>MAPT:</italic> mean age±SD = 60.92±7.60, sex = 7M/6F</p></list-item></list>
<break/><bold>14 control donors:</bold> mean age±SD =78.43±11.76 years, sex =5M/9F</td><td align="left" valign="top"><italic>˜0 + disease + age + sex + SOX10<sup>+</sup> proportions + Double proportions + array + slide</italic> (0 surrogate variables detected)</td></tr><tr><td align="left" valign="top"><bold>FTLD3</bold> [<xref ref-type="bibr" rid="R83">83</xref>]</td><td align="left" valign="top">FTLD-tau (sporadic PSP)</td><td align="left" valign="top"><bold>93 FTLD donors:</bold> mean age±SD = 71.16±5.32, sex = 54M/39F
<break/><bold>70 control donors:</bold> mean age±SD = 76.17±7.93, sex = 45M/25F</td><td align="left" valign="top"><italic>˜0 + disease + age + sex + SOX10<sup>+</sup>(f proportions + Double proportions + array + slide + surrogate variable</italic> (1/1 surrogate variables detected)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P49">FTLD – Frontotemporal lobar degeneration; FTLD-TDP – FTLD with 4311kDa transactive response DNA-binding protein (TDP-43) positive inclusions; FTLD-Tau – FTLD with tau positive inclusions; FTDP-17 – frontotemporal dementia and parkinsonism linked to chromosome 17; PSP – progressive supranuclear palsy; SD – Standard deviation; F – Females; M – Males; Double’ proportions – NeuN<sup>-</sup>/SOXlO<sup>-</sup> proportions.</p></fn></table-wrap-foot></table-wrap></floats-group></article>